var title_f39_55_40816="Patient position for femoral vascular access";
var content_f39_55_40816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Patient position for femoral vascular access",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hip should be flexed and externally rotated and a towel roll placed to facilitate an easy approach to the femoral vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Torrey SB, Saladino RA. Arterial puncture and catheterization. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40816=[""].join("\n");
var outline_f39_55_40816=null;
var title_f39_55_40817="Barium enema cecal volvulus";
var content_f39_55_40817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Barium enema cecal volvulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The single contrast barium enema (A) shows a contrast column reaching the region of the cecum via the decompressed descending colon, transverse colon, and ascending colon. As it reaches the region of the cecum it is obstructed manifesting with beak shaped morphology (arrow) with no contrast entering the air filled and distended cecum (between arrowheads). In B, the site of the volvulus is again noted (arrow). These findings confirm the diagnosis of a cecal volvulus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40817=[""].join("\n");
var outline_f39_55_40817=null;
var title_f39_55_40818="Age related trabecular loss";
var content_f39_55_40818=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Age-related loss of trabecular bone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 201px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential trabecular loss as shown by histologic examination of bone specimens; the vertical trabeculae are shown in yellow, the horizontal in blue-green. First panel: Normal 50-year-old man with an almost perfect continuous trabecular network. Second panel: 58-year-old man with thinning of the horizontal trabeculae and some loss of continuity. Third panel: 76-year-old man with continued thinning of the horizontal trabeculae and wider separation of the vertical structures. Fourth panel: 87-year-old woman with advanced breakdown of the entire network showing unsupported vertical trabeculae. The third and fourth panels represent the degree of loss of bone mass and microarchitectural deterioration that is generally defined as osteoporosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Mosekilde, LI, Bone 1988; 9:247. Reprinted with permission from Pergamon Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40818=[""].join("\n");
var outline_f39_55_40818=null;
var title_f39_55_40819="Centrilobular emphysema";
var content_f39_55_40819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F82308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F82308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Centrilobular emphysema pulmonary hypertension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial CT images confirm the presence of centrilobular (centriacinar) emphysema (A) and pulmonary hypertension (B). The lung parenchyma shows lucent spaces of parenchymal destruction interspersed among normal lung tissue best appreciated in the right upper lobe (A). The main pulmonary artery (arrow) measures 3.8 cm (normal &lt;2.9 cm). The pulmonary artery and aorta should be about the same size and in this case the main pulmonary artery is larger than the companion ascending aorta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40819=[""].join("\n");
var outline_f39_55_40819=null;
var title_f39_55_40820="White-centered hemorrhages";
var content_f39_55_40820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    White-centered hemorrhages",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White-centered hemorrhages in the optic fundi of patients with cerebral malaria. The image on the right is from a patient with hemorrhages and whitening (prominently seen around the macula).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan Lewallen and Nicholas Beare.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40820=[""].join("\n");
var outline_f39_55_40820=null;
var title_f39_55_40821="Mepivacaine: Drug information";
var content_f39_55_40821=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mepivacaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/7/42099?source=see_link\">",
"    see \"Mepivacaine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/5/20564?source=see_link\">",
"    see \"Mepivacaine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg;;",
"     </li>",
"     <li>",
"      Polocaine&reg;;",
"     </li>",
"     <li>",
"      Polocaine&reg; MPF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg;;",
"     </li>",
"     <li>",
"      Polocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F192962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F192934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Injectable local anesthetic:",
"     </b>",
"     Dose varies with procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. The smallest dose and concentration required to produce the desired effect should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Maximum single or total dose given for one procedure:",
"     </i>",
"     400 mg; 500 mg if epinephrine has been added (Barash, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Cervical, brachial, intercostal, pudendal nerve block:",
"     </i>",
"     5-40 mL of a 1% solution (maximum: 400 mg)",
"     <b>",
"      or",
"     </b>",
"     5-20 mL of a 2% solution (maximum: 400 mg). For pudendal block, inject one-half the total dose each side.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Transvaginal block (paracervical plus pudendal):",
"     </i>",
"     Up to 30 mL (total for both sides) of a 1% solution (maximum: 300 mg). Inject one-half the total dose each side.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Paracervical block:",
"     </i>",
"     Up to 20 mL (total for both sides) of a 1% solution (maximum: 200 mg). Inject one-half  the total dose to each side. This is the maximum recommended dose per 90-minute procedure; inject slowly with 5 minutes between sides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Caudal and epidural block (preservative free solutions only):",
"     </i>",
"     15-30 mL of a 1% solution (maximum: 300 mg)",
"     <b>",
"      or",
"     </b>",
"     10-25 mL of a 1.5% solution (maximum: 375 mg)",
"     <b>",
"      or",
"     </b>",
"     10-20 mL of a 2% solution (maximum: 400 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Infiltration:",
"     </i>",
"     Up to 40 mL of a 1% solution (maximum: 400 mg); up to 50 mL if epinephrine has been added (maximum:  500 mg) (Barash, 2009); an equivalent amount of a 0.5% solution (prepared by diluting the 1% solution with NS) may be used for large areas",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Peripheral nerve block to provide a surgical level of anesthesia (Miller, 2010):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Major nerve block (blockade of two or more distinct nerves, a nerve plexus, or very large nerves at more proximal sites:  30-50 mL of a 1% or 1.5% solution (maximum: 500 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Minor nerve block (blockade of a single nerve [eg, ulnar or radial]): 5-20 mL of a 1% solution (maximum: 200 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Therapeutic block:",
"     </i>",
"     1-5 mL of 1% solution (maximum: 50 mg)",
"     <b>",
"      or",
"     </b>",
"     1-5 mL of 2% solution (maximum: 100 mg)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F192949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/5/20564?source=see_link\">",
"      see \"Mepivacaine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Injectable local anesthetic:",
"     </b>",
"     Dose varies with procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. The smallest dose and concentration required to produce the desired effect should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Maximum single or total dose given for one procedure:",
"     </i>",
"     5-6 mg/kg; only concentrations &lt;2% should be used in children &lt;3 years or &lt;14 kg (30 lbs)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F192935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased doses suggested by manufacturer&rsquo;s labeling; however, no dosing adjustments provided. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbocaine&reg;: 1% [10 mg/mL] (50 mL); 2% [20 mg/mL] (50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polocaine&reg;: 1% [10 mg/mL] (50 mL); 2% [20 mg/mL] (50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbocaine&reg;: 1% [10 mg/mL] (30 mL); 1.5% [15 mg/mL] (30 mL); 2% [20 mg/mL] (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polocaine&reg; MPF: 1% [10 mg/mL] (30 mL); 1.5% [15 mg/mL] (30 mL); 2% [20 mg/mL] (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F192916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before injecting, withdraw syringe plunger to ensure injection is not into vein or artery.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F192915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local or regional analgesia; anesthesia by local infiltration, peripheral and central neural techniques (epidural and caudal);",
"     <b>",
"      not",
"     </b>",
"     for use in spinal anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F192969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mepivacaine may be confused with bupivacaine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Polocaine&reg; may be confused with prilocaine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F192960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Degree of adverse effects in the CNS and cardiovascular system is directly related to the blood levels of mepivacaine, route of administration, and physical status of the patient. The effects below are more likely to occur after systemic administration rather than infiltration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrest, cardiac output decreased, heart block, hyper-/hypotension, myocardial depression, syncope, tachycardia, ventricular arrhythmias",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, convulsions, depression, dizziness, excitation, restlessness, tremors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, diaphoresis, erythema, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Fecal incontinence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Incontinence, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chondrolysis (continuous intra-articular administration), paralysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, pupil constriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, hypoventilation, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylactoid reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F192919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mepivacaine, other amide-type local anesthetics, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F192906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is",
"     <b>",
"      not",
"     </b>",
"     an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill patients; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Preservative-containing solutions: Do not use solutions containing preservatives for caudal or epidural block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Test dose: A test dose is recommended prior to epidural administration and all reinforcing doses with continuous catheter technique.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2234302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Mepivacaine has been used in obstetrical analgesia.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F192937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Carbocaine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (50 mL): $7.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (50 mL): $8.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Carbocaine Preservative-Free Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 mL): $5.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5% (30 mL): $5.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (20 mL): $6.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Mepivacaine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (1.8 mL): $0.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Polocaine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (50 mL): $11.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (50 mL): $11.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Polocaine-MPF Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 mL): $8.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5% (30 mL): $11.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (20 mL): $9.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2234306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs, state of consciousness; signs of CNS toxicity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F192922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocain (DK, SE);",
"     </li>",
"     <li>",
"      Carbocain Dental (NO);",
"     </li>",
"     <li>",
"      Carbocaina (IT);",
"     </li>",
"     <li>",
"      Carbocaine Dental (PL, ZA);",
"     </li>",
"     <li>",
"      Carbocaine HCl (FR);",
"     </li>",
"     <li>",
"      Isocaine 3% (IL);",
"     </li>",
"     <li>",
"      Lentocaine (MX);",
"     </li>",
"     <li>",
"      Meaverin (DE);",
"     </li>",
"     <li>",
"      Mepicaton 3% (TH);",
"     </li>",
"     <li>",
"      Mepidont (PL);",
"     </li>",
"     <li>",
"      Mepigobbi (AR);",
"     </li>",
"     <li>",
"      Mepivastesin (CZ, HK, IL, PL, SG);",
"     </li>",
"     <li>",
"      Scandicain (AT, CH);",
"     </li>",
"     <li>",
"      Scandicaine (BE, LU, NL);",
"     </li>",
"     <li>",
"      Scandinibsa (ES, PT);",
"     </li>",
"     <li>",
"      Scandonest (AU, BG, EE, FI, NZ);",
"     </li>",
"     <li>",
"      Scandonest Sans Vasoconstricteur (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F192905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mepivacaine is an amide local anesthetic similar to lidocaine; like all local anesthetics, mepivacaine acts by preventing the generation and conduction of nerve impulses",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F192918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action (route and dose dependent): Range: 3-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (route and dose dependent): 2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic via N-demethylation, hydroxylation, and glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Neonates: 8.7-9 hours; Adults: 1.9-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90% to 95% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barash PG, Cullen BF, Stoelting RK, et al, eds,",
"      <i>",
"       Clinical Anesthesia",
"      </i>",
"      , 6th ed, Philadelphia, PA; Lippincott Williams &amp; Wilkins, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dix SK, Rosner GF, Nayar M, et al, &ldquo;Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2011, 39(4):872-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40821/abstract-text/21263316/pubmed\" id=\"21263316\" target=\"_blank\">",
"        21263316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dodson WE, Hillman RE, and Hillman LS, &ldquo;Brain Tissue Levels in a Fatal Case of Neonatal Mepivacaine (Carbocaine&reg;) Poisoning,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1975, 86(4):624-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40821/abstract-text/1127509/pubmed\" id=\"1127509\" target=\"_blank\">",
"        1127509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foxall G, McCahon R, Lamb J, et al, \"Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,\"",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2007, 62(5):516-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40821/abstract-text/17448066/pubmed\" id=\"17448066\" target=\"_blank\">",
"        17448066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Litz RJ, Popp M, Stehr SN, et al, \"Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion,\"",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2006, 61(8):800-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40821/abstract-text/16867094/pubmed\" id=\"16867094\" target=\"_blank\">",
"        16867094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller RD,",
"      <i>",
"       Miller&rsquo;s Anesthesia",
"      </i>",
"      ,  7th ed, Philadelphia PA: Churchill Livingstone, 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo JM, Dasta JF, Kleinschmidt KC, et al, &ldquo;State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2010, 44(4):688-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40821/abstract-text/20332339/pubmed\" id=\"20332339\" target=\"_blank\">",
"        20332339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore PA and Hersh EV, \"Local Anesthetics: Pharmacology and Toxicity,\"",
"      <i>",
"       Dent Clin North Am",
"      </i>",
"      , 2010, 54(4):587-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40821/abstract-text/20831923/pubmed\" id=\"20831923\" target=\"_blank\">",
"        20831923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neal JM, Mulroy MF, and Weinberg GL, &ldquo;American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,&rdquo;",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2012, 37(1):16-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40821/abstract-text/22189574/pubmed\" id=\"22189574\" target=\"_blank\">",
"        22189574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenblatt MA, Abel M, Fischer GW, et al, \"Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2006, 105(1):217-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40821/abstract-text/16810015/pubmed\" id=\"16810015\" target=\"_blank\">",
"        16810015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Torres MJ, Garcia JJ, del Cano Moratinos AM, et al, &ldquo;Fixed Drug Eruption Induced by Mepivacaine,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1995, 96(1):130-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40821/abstract-text/7622755/pubmed\" id=\"7622755\" target=\"_blank\">",
"        7622755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9610 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40821=[""].join("\n");
var outline_f39_55_40821=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192931\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192932\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192962\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192934\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192949\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192935\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192914\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192902\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192916\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192915\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192969\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192960\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192919\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192906\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299669\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221552\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192911\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2234302\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192937\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323371\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2234306\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192922\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192905\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192918\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9610\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9610|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/7/42099?source=related_link\">",
"      Mepivacaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/5/20564?source=related_link\">",
"      Mepivacaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_55_40822="Saxagliptin and metformin: Drug information";
var content_f39_55_40822=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Saxagliptin and metformin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/59/4022?source=see_link\">",
"    see \"Saxagliptin and metformin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16339639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Investigating Unpublished Reports of Pancreatic Toxicity With Incretin Mimetic Drugs",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is evaluating unpublished new findings that suggest an increased risk of pancreatitis and pancreatic duct metaplasia in patients with type 2 diabetes treated with incretin mimetics. These findings are based on pancreatic tissue samples taken from patients who died from unspecified causes. The FDA has requested these samples, as well as information on the methodology used to collect them, and will communicate its final conclusions and recommendations. Healthcare providers should continue to prescribe incretin mimetics according to the drug label recommendations and patients receiving incretin mimetics are advised to continue therapy as directed and to discuss any concerns with their healthcare provider.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at the following website:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11391630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10967453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kombiglyze&trade; XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10967456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Biguanide;",
"     </li>",
"     <li>",
"      Antidiabetic Agent, Dipeptidyl Peptidase IV (DPP-IV) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11391706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Oral: Initial doses should be based on current dose of saxagliptin and metformin; daily doses should be given once daily with the evening meal. Maximum: Saxagliptin 5 mg/metformin 2000 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Patients inadequately controlled on metformin alone:",
"     </i>",
"     Initial dose: Saxagliptin 2.5-5 mg/day plus current dose of metformin.",
"     <b>",
"      Note:",
"     </b>",
"     Patients who require saxagliptin 2.5 mg (eg, dose adjusted for concomitant use of strong CYP3A4/5 inhibitors) and metformin &gt;1000 mg should not be switched to the combination product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Patients inadequately controlled on saxagliptin alone:",
"     </i>",
"     Initial dose: Metformin 500 mg/day plus saxagliptin 5 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Metformin-na&iuml;ve patients currently receiving saxagliptin 2.5 mg daily (eg, dose adjusted for concomitant use of strong CYP3A4/5 inhibitors) should not be switched to the combination product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Concomitant use with strong CYP3A4/5 inhibitors:",
"     </i>",
"     Maximum: Saxagliptin 2.5 mg/metformin 1000 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Concomitant use with insulin or insulin secretagogues:",
"     </i>",
"     Reduced dose of insulin or insulin secretagogues (eg, sulfonylureas) may be needed.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11391707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor). Do not use in patients &ge;80 years of age unless normal renal function has been established.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11391709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use in patients with renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL [&ge;136 micromole/L] in males or &ge;1.4 mg/dL [&ge;124 micromole/L] in females or abnormal clearance).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11391708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid metformin; liver disease is a risk factor for the development of lactic acidosis during metformin therapy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11391815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, variable release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kombiglyze&trade; XR 2.5/1000: Saxagliptin 2.5 mg [immediate release] and metformin hydrochloride 1000 mg [extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kombiglyze&trade; XR 5/500: Saxagliptin 5 mg [immediate release] and metformin hydrochloride 500 mg [extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kombiglyze&trade; XR 5/1000: Saxagliptin 5 mg [immediate release] and metformin hydrochloride 1000 mg [extended release]",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13376299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM280360.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM280360.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11391710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer once daily with the evening meal. Swallow whole; do not crush, cut, or chew tablets.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10967457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise when treatment with both saxagliptin and metformin is appropriate",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11391631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Saxagliptin and Metformin may be confused with sitaGLIPtin and Metformin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11391643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11391639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to saxagliptin, metformin, or any component of the formulation; renal impairment (eg, serum creatinine &ge;1.5 mg/dL [&ge;136 &mu;mol/L] in males or &ge;1.4 mg/dL [&ge;124 &mu;mol/L] in females) which may also result from conditions such as cardiovascular collapse, acute myocardial infarction, and septicemia; acute or chronic metabolic acidosis including diabetic ketoacidosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11391640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Rare hypersensitivity reactions, including anaphylaxis, angioedema, and exfoliative dermatologic reactions have been reported with saxagliptin use; discontinue if signs/symptoms of severe hypersensitivity reaction occur. Events have generally been noted within the first 3 months of therapy, and may occur with the initial dose. Use with caution if patient has experienced angioedema with other DPP-IV inhibitor use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis:",
"     <b>",
"      [U.S. Boxed Warning]: Lactic acidosis is a rare, but potentially severe consequence of therapy with metformin.",
"     </b>",
"     Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue metformin in clinical situations predisposing to hypoxemia, including conditions such as cardiovascular collapse, respiratory failure, acute myocardial infarction, acute congestive heart failure, and septicemia. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Cases of acute pancreatitis have been reported with saxagliptin use. Monitor for signs/symptoms of pancreatitis; discontinue use immediately if pancreatitis is suspected and initiate appropriate management. Use with caution in patients with a history of pancreatitis as it is not known if this population is at greater risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetic ketoacidosis (DKA): Saxagliptin should not be used in patients with DKA due to lack of efficacy in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with congestive heart failure requiring pharmacologic management, particularly in patients with unstable acute heart failure; risk of lactic acidosis may be increased secondary to hypoperfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Avoid metformin use in patients with impaired liver function due to potential for lactic acidosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Metformin is substantially excreted by the kidney; patients with renal function below the limit of normal for their age should not receive therapy. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Type 1 diabetes mellitus: Saxagliptin should not be used in patients with type 1 diabetes mellitus (insulin dependent, IDDM) due to lack of efficacy in this patient population",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4/5 inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin; also see Drug Interactions); dosage adjustment of saxagliptin is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin: Concomitant use of insulin may increase the risk of hypoglycemia. Monitor blood glucose closely; dosage reduction of insulin may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin secretagogues: Concomitant use of an insulin secretagogue (eg, sulfonylurea) may increase the risk of hypoglycemia. Monitor blood glucose closely; dosage reduction of secretagogues may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Metformin should not be initiated in patients &ge;80 years of age unless normal renal function is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release tablet: The inactive ingredients may appear in the stool as a soft mass resembling the tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iodinated contrast: Metformin therapy should be temporarily discontinued prior to or at the time of intravascular administration of iodinated contrast media (potential for acute alteration in renal function). Metformin should be withheld for 48 hours after the radiologic study and restarted only after renal function has been confirmed as normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical procedures: Therapy should be suspended for any surgical procedures (resume only after normal intake resumed and normal renal function is verified).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     concentrations: May impair vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     absorption, particularly in those with inadequate vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     or calcium intake/absorption; very rarely associated with anemia. Rapid reversal of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency may be observed with discontinuation of therapy or supplementation. Monitor vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     serum concentrations periodically with long-term therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F11391666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11304694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: DPP-IV Inhibitors may enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers: May decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Saxagliptin. Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: May increase the serum concentration of MetFORMIN. MetFORMIN may increase the serum concentration of Dalfampridine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trospium: MetFORMIN may decrease the serum concentration of Trospium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F11391667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Excessive ethanol intake (acute or chronic) should be avoided due to increased risks for metformin accumulation and lactic acidosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Use caution with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle; may increase risk of hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11391635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11391636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination. Adverse events were not observed in animal studies of the individual agents; therefore, saxagliptin/metformin is classified as pregnancy category B. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11391637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: Excretion in breast milk unknown/use caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metformin: Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11391638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Kombiglyze XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-1000 mg (60): $295.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-500 mg (30): $295.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-1000 mg (30): $295.13",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11391812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma glucose; Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; hematologic parameters (eg, hemoglobin/hematocrit and red blood cell indices); hepatic function; renal function (prior to initiation of therapy then annually or more frequent if necessary); vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     (periodically with long-term treatment) and folate (if megaloblastic anemia is suspected)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F11391811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11391670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Saxagliptin inhibits dipeptidyl peptidase IV (DPP-IV) enzyme resulting in prolonged active incretin levels. Incretin hormones (eg, glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and decreasing glucagon secretion from pancreatic alpha cells. Decreased glucagon secretion results in decreased hepatic glucose production. Under normal physiologic circumstances, incretin hormones are released by the intestine throughout the day and levels are increased in response to a meal; incretin hormones are rapidly inactivated by the DPP-IV enzyme.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Metformin decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11391672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40822/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeFronzo RA, Hissa MN, Garber AJ, et al, &ldquo;The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes on Metformin Alone,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(9):1649-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40822/abstract-text/19478198/pubmed\" id=\"19478198\" target=\"_blank\">",
"        19478198",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40822/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al, &ldquo;Saxagliptin Given in Combination With Metformin as Initial Therapy Improves Glycaemic Control in Patients With Type 2 Diabetes compared With Either Monotherapy: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Diabetes Obesity Metab",
"      </i>",
"      , 2009, 11(6):611-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40822/abstract-text/19515181/pubmed\" id=\"19515181\" target=\"_blank\">",
"        19515181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse, JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40822/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/55/40822/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16090 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40822=[""].join("\n");
var outline_f39_55_40822=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16339639\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391630\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10967453\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10967456\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391706\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391707\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391709\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391708\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391815\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376299\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391710\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10967457\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391631\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391643\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391639\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391640\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391666\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11304694\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391667\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391635\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391636\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391637\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391638\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322876\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391812\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391811\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391670\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391672\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16090\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16090|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/59/4022?source=related_link\">",
"      Saxagliptin and metformin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_55_40823="Saline infusion sonohysterography";
var content_f39_55_40823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Saline infusion sonohysterography",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/55/40823/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/55/40823/contributors\">",
"     Steven R Goldstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/55/40823/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/55/40823/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/55/40823/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/55/40823/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/55/40823/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/55/40823/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saline infusion sonohysterography refers to a procedure in which fluid is instilled into the uterine cavity transcervically to provide enhanced endometrial visualization during transvaginal ultrasound examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The technique improves sonographic detection of endometrial pathology, such as polyps, hyperplasia, cancer, leiomyomas, and adhesions. In addition, it can help avoid invasive diagnostic procedures in some patients as well as optimize the preoperative triage process for those women who require therapeutic intervention. It is easily and rapidly performed at minimal cost, well-tolerated by patients, and is virtually devoid of complications. The American College of Obstetricians and Gynecologists, in conjunction with the American College of Radiology and the American Institute of Ultrasound in Medicine, developed a technology assessment document for saline infusion sonohysterography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of situations where fluid enhanced endovaginal scanning will aid evaluation of the uterine cavity. The American Institute for Ultrasound in Medicine's standard indications and contraindications to this procedure are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef73097 \" href=\"mobipreview.htm?6/51/6971\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Unscheduled uterine bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unexpected uterine bleeding accounts for a large proportion of gynecologic patient visits. Endometrial biopsy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    office hysteroscopy are often used as initial diagnostic procedures; in hospital dilation and curettage is no longer considered an appropriate initial diagnostic test in most women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transvaginal ultrasound is used increasingly as an initial triage for patients with abnormal uterine bleeding. Sonohysterography is a subset of transvaginal sonography that is used when it is difficult to visualize the endometrium or the endometrium is thickened.",
"   </p>",
"   <p>",
"    Sonohysterography is particularly useful for finding focal endometrial abnormalities or confirming that a focal abnormality diagnosed by transabdominal or transvaginal ultrasound is present and better defining the nature of the abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As an example, one study performed both transvaginal ultrasonographic examination and sonohysterography on 106 patients with menometrorrhagia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/8\">",
"     8",
"    </a>",
"    ]. The sensitivity and specificity of saline infusion sonohysterography for detection of polyps were significantly higher than for transvaginal ultrasound alone (93 and 94 versus 75 and 76 percent for TVS) and were comparable to hysteroscopy, a finding confirmed by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a prospective series of 214 consecutive pre- and postmenopausal women with abnormal uterine bleeding and a suspected uterine abnormality on TVS found an initial approach of sonohysterography followed by hysteroscopy, if needed for diagnosis or therapy, was preferable to routinely proceeding to diagnostic hysteroscopy because the latter could be avoided in 84 percent of patients (sonohysterography was conclusive in 180 of 214 women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/13\">",
"     13",
"    </a>",
"    ]. Although some women subsequently underwent operative hysteroscopy for treatment of uterine abnormalities, an initial approach using diagnostic hysteroscopy under conditions allowing operative hysteroscopy if needed was also deemed unsatisfactory because preparation for the combined procedure requires general or regional anesthesia, despite the knowledge that a significant portion of women will have no anatomic abnormality and will not have a surgical intervention.",
"   </p>",
"   <p>",
"    In addition, sonohysterography can help to reliably distinguish between:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premenopausal women with anovulatory bleeding, which is best treated hormonally, from those with an anatomic lesion, which may require tissue sampling for histologic diagnosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      resection for treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23944?source=see_link\">",
"       \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postmenopausal women with bleeding due to atrophy, the most common cause of bleeding in this age group, from those with anatomic lesions that might require tissue sampling to exclude carcinoma or for treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2711?source=see_link\">",
"       \"Postmenopausal uterine bleeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with focal abnormalities best biopsied under direct hysteroscopic visualization from those with global abnormalities that can be sampled blindly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women with abnormal uterine bleeding in whom endometrial sampling is indicated should have saline instillation sonohysterography prior to the sampling procedure. Blind sampling procedures are justified if an abnormality is symmetrically 'pan uterine'. When focal lesions (eg, polyps, fibroids, some hyperplasias, some carcinomas) are detected, then directed biopsies are preferable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial assessment is part of the routine evaluation of infertility and recurrent pregnancy loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26679?source=see_link\">",
"     \"Evaluation of couples with recurrent pregnancy loss\"",
"    </a>",
"    .) Saline infusion sonohysterography is useful for detecting potential anatomic causes of reduced fertility, such as submucous myomas, endometrial polyps, anomalies, and intrauterine adhesions and appears comparable to or better than hysterosalpingography (HSG) or hysteroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/1,2,15-18\">",
"     1,2,15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, an outline of the fallopian tubes (as seen with HSG) is not observed with sonohysterography. Accretion of instilled fluid in the posterior cul-de-sac is a sign of patency of at least one tube.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tamoxifen-induced changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    , a potent antiestrogen, is being used extensively as adjunctive chemotherapy in women with estrogen receptor-positive breast cancer. Some patients taking tamoxifen, when viewed with endovaginal ultrasound, will display thickened central uterine echoes. These changes are sometimes polyps or abnormal endometrial tissue (proliferative, hyperplasia, or even cancer). However, sonohysterography has shown that these changes can often represent microcysts of the basalis of the endometrium or proximal myometrium that develop due to reactivation of focal adenomyosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, sonohysterography can help to define suspected endometrial abnormalities noted on transvaginal ultrasound examination and avoid tissue sampling (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70071 graphicRef62592 \" href=\"mobipreview.htm?28/20/28999\">",
"     image 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80525 \" href=\"mobipreview.htm?32/45/33503\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine sonographic screening of the endometrium of asymptomatic women taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    has not been recommended by the American College of Obstetricians and Gynecologists (ACOG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/23\">",
"     23",
"    </a>",
"    ]. This is a controversial area; some investigators have proposed that patients embarking on tamoxifen therapy should have pretreatment screening to determine if they have underlying endometrial abnormalities, such as polyps or endometrial hyperplasia, which place them at high risk of developing into or progressing to atypical hyperplasia. Such patients warrant ongoing periodic surveillance, which is best accomplished by transvaginal ultrasound and then sonohysterography if the endometrial echo is not adequately seen or not reliably thin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/24\">",
"     24",
"    </a>",
"    ]. Low risk patients could be followed according to the ACOG guidelines, which are briefly described above and in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41576?source=see_link&amp;anchor=H94636198#H94636198\">",
"     \"Managing the side effects of tamoxifen\", section on 'Screening for uterine tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination is typically scheduled early in the follicular phase of the cycle, after menstrual flow has ceased and before day 10, as the endometrium is very thin at this point in the cycle. Later in the cycle, focal irregularities in the contour of the endometrium may be mistaken for small polyps or focal areas of endometrial hyperplasia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74592 \" href=\"mobipreview.htm?29/13/29906\">",
"     image 2",
"    </a>",
"    ). One prospective blinded study reported a 27 percent false positive rate in sonohysterography performed from day 16 to 28, but no false positive when the procedure was performed prior to day 10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/25\">",
"     25",
"    </a>",
"    ]. Sometimes the patient has such irregular bleeding that she cannot tell what is an actual menses. In such cases, it can be helpful to use an empiric course of a progestin, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    10 mg daily for 10 days, to create a \"medical curettage\" and then time the ultrasound evaluation to the withdrawal bleed.",
"   </p>",
"   <p>",
"    Anesthesia or analgesia is not required as the intrauterine insemination catheter is relatively painless while being inserted. The procedure is well tolerated by the overwhelming majority of patients; a few experience minimal cramping.",
"   </p>",
"   <p>",
"    A bimanual examination may be performed initially to determine the position and mobility of the uterus, although the initial transvaginal sonography can usually determine the degree of anteversion or retroversion, if present. The speculum is inserted and the cervix cleansed with a 10 percent iodine-based solution. A variety of commercially available sonohysterography catheters can be utilized. Most of these have similar efficacy, but vary in small design elements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/26\">",
"     26",
"    </a>",
"    ]. Insertion can be with ring forceps, using a spear-like motion (for less flexible catheters), or with an internal stylet. To prevent run back of fluid, some employ an acorn-like device and others have a balloon.",
"   </p>",
"   <p>",
"    The catheter should be flushed with sterile saline or water prior to insertion to rid it of small amounts of air, which would cause an echogenic artifactual appearance. The speculum is then removed carefully to avoid dislodging the catheter. The catheter will still extend beyond the introitus when positioned in the uterus.",
"   </p>",
"   <p>",
"    When a balloon catheter is employed, it appears that intracervical catheter placement causes less pain and requires less saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/27\">",
"     27",
"    </a>",
"    ]. In a small randomized trial, women who had intracervical rather than intrauterine catheter placement reported significantly less pain at initial catheter balloon inflation and also required 50 percent less saline to perform the procedure. The catheter is inserted to the fundus by grasping the catheter with a ring forceps and gently feeding it through the cervical os.",
"   </p>",
"   <p>",
"    The vaginal probe is then reinserted and a syringe filled with sterile fluid rid of air bubbles is attached to the catheter. Fluid is instilled while the transducer is moved from side to side (cornua to cornua) in a long axis projection. The amount of instilled fluid will vary, depending upon the image produced on the ultrasound monitor.",
"   </p>",
"   <p>",
"    After the uterus has been completely surveyed from cornua to cornua in a long-axis projection, the transducer is rotated 90 degrees into a coronal plane. More fluid is instilled while fanning down towards the endocervical canal and up towards the uterine fundus to recreate three-dimensional anatomy. Every portion of the uterine cavity should be imaged, because polyps, hyperplasia, or carcinomas may be focal. A reliable assessment requires that the endometrial echo be homogeneous, surrounded by an intact hypoechoic junctional zone, and that the operator constantly remember that the endometrial cavity is a three-dimensional structure. Failure to meticulously recreate three dimensional anatomy will result in error.",
"   </p>",
"   <p>",
"    Three-dimensional ultrasound equipment will eliminate error that may occur if the operator does not pay meticulous attention to mentally recreating three dimensional anatomy. It usually requires a balloon catheter to prevent run back of fluid and results in increased patient cramping and discomfort. A prospective study showed no advantage of three-dimension sonohysterography over two-dimensional [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/28\">",
"     28",
"    </a>",
"    ], although both types had significantly better sensitivity and specificity than ultrasound without fluid enhancement.",
"   </p>",
"   <p>",
"    Some initial reports utilizing a hydroxyethyl cellulose gel containing anesthetic and antiseptic agents have proposed this as an alternative to saline or water. This may allow stable filling of the cavity without continuous injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal sonohysterogram is shown for comparison with the abnormalities below (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74520 \" href=\"mobipreview.htm?39/32/40449\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Polyp",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical sonohysterographic appearance of an endometrial polyp is a well-defined, homogeneous, polypoid lesion isoechoic to the endometrium with preservation of the endometrial-myometrial interface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/30\">",
"     30",
"    </a>",
"    ]. Atypical features include cystic components, multiple polyps, broad base, and hypoechogenicity or heterogeneity. Transvaginal sonograms before and after saline infusion in a patient with abnormal uterine bleeding due to an endometrial polyp are provided (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63414 graphicRef71802 \" href=\"mobipreview.htm?5/25/5526\">",
"     image 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The use of color flow or power Doppler for identifying the central feeder vessel pathognomonic of an endometrial polyp is an alternative to sonohysterography in the diagnosis of polyps (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57653 \" href=\"mobipreview.htm?5/37/5715\">",
"     image 5",
"    </a>",
"    ). In one study, this techniques had a positive predictive value of 81.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Leiomyoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Submucosal fibroids are usually well-defined, broad-based, hypoechoic, solid masses with shadowing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/30\">",
"     30",
"    </a>",
"    ]. The overlying layer of endometrium is echogenic and distorts the endometrial-myometrial interface. Atypical features include pedunculation or a multilobulated surface. Sonohysterography's major benefit over transvaginal ultrasound alone is that it more accurately shows how much of the fibroid projects into the endometrial cavity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55785 graphicRef50777 \" href=\"mobipreview.htm?2/5/2134\">",
"     image 6A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/30,32\">",
"     30,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hyperplasia and cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial hyperplasia usually appears as diffuse echogenic endometrial thickening without focal abnormality, although focal lesions can occur (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75181 graphicRef60457 \" href=\"mobipreview.htm?27/38/28263\">",
"     image 7A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81230 \" href=\"mobipreview.htm?15/45/16095\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/30\">",
"     30",
"    </a>",
"    ]. Endometrial cancer is typically a diffuse process, but early cases can be focal and can appear as a polypoid mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adhesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesions usually appear as mobile, thin, echogenic bands that cut across the endometrial cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/30\">",
"     30",
"    </a>",
"    ]. Less commonly, they are thick, broad-based bands or completely obliterate the endometrial cavity (Asherman syndrome).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5523488\">",
"    <span class=\"h2\">",
"     Adenomyosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have observed communication between the endometrial cavity and adenomyotic lesions during saline infusion sonohysterography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/33\">",
"     33",
"    </a>",
"    ]. These were saline-filled defects extending from the endometrial cavity into the myometrium. Other experts claim that this entity is not adenomyotic, but rather represents a different process which has been named &ldquo;endometrial-subendometrial myometrium unit disruption disease&rdquo; and may have an influence on fertility and outcome of assisted reproductive techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5523531\">",
"    <span class=\"h2\">",
"     Endometrial assessment after non-resectoscopicl endometrial ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-resectoscopic endometrial ablation has become a popular alternative to hysterectomy for treatment of heavy menstrual bleeding. When patients who have undergone this type of procedure subsequently have abnormal premenopausal bleeding or postmenopausal bleeding, routine methods of endometrial evaluation are often suboptimal, including sonohysterography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TECHNICAL CONCERNS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Difficulty passing the catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, it will be difficult to thread the flexible catheter into place because of cervical stenosis, uterine position, or abnormal uterine contour. Changing the toe of the speculum by moving the handle up or down may change the angle of the cervix with the fundus and will often allow successful insertion of the catheter. A catheter with a stylet or one made of less flexible material also can be useful. A cervical stabilizer rather than a standard tenaculum is another acceptable option. Medical or mechanical dilation may be necessary in some women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Poor visualization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saline infusion sonohysterography, unlike hysteroscopy, does not require distension of the uterine cavity. Even a small ribbon of sonolucent fluid will allow good visualization of endometrial contents on either side of the fluid. However, women with a patulous cervix may not retain even the small amount of fluid needed to visualize the endometrium. Sometimes there is excessive leakage of fluid out the fallopian tubes. Slow injection of fluid using minimal pressure can sometimes overcome these problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of upper genital tract infection is similar to that with hysteroscopy or traditional hysterosalpingogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Obtaining appropriate cultures and prescribing prophylactic antibiotics depend upon the patient's risk factors and clinician preference. Risk factors for pelvic infection include women with multiple partners, having a partner with dysuria or urethral discharge, young age, and previous sexually transmitted disease or pelvic inflammatory disease. Routine use of prophylactic antibiotics is not warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Dissemination of carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns regarding the dissemination of malignant cells during saline infusion sonohysterography have been addressed in various studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/39\">",
"     39",
"    </a>",
"    ]. In one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/40\">",
"     40",
"    </a>",
"    ], 14 women with known endometrial cancer underwent sonohysterography in the operating room prior to their surgical hysterectomy and staging procedure. In cell washings, malignant cells could be identified in only",
"    <span class=\"nowrap\">",
"     1/14",
"    </span>",
"    (7 percent) of cases.",
"   </p>",
"   <p>",
"    In another similar study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/41\">",
"     41",
"    </a>",
"    ], 32 women with known carcinoma had sonohysterography in the operating room during their surgery. The fluid that spilled from the fallopian tubes was collected. Malignant cells were identified in only",
"    <span class=\"nowrap\">",
"     2/32",
"    </span>",
"    (6 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38744?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\", section on 'Risk of tumor dissemination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     False positive findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;False positive findings (ie, suspected pathology not confirmed by hysteroscopy) have been attributed to blood clots, intrauterine debris, mucus plugs, shearing of normal endometrium, thickened endometrial folds, and misidentified endometrial fragments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procedure-related side effects and complications are mild and uncommon. A prospective study of 1153 women age 23 to 64 years undergoing saline infusion sonohysterography reported the following: failure to complete the procedure (7 percent), pelvic pain (3.8 percent), vagal symptoms (3.5 percent), nausea (1 percent), and postprocedure fever (0.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/44\">",
"     44",
"    </a>",
"    ]. In patients who failed to complete the procedure, a second attempt on another day was always successful when these issues were addressed (eg, use of dilators for cervical stenosis,",
"    <span class=\"nowrap\">",
"     analgesia/local",
"    </span>",
"    anesthesia for patients with significant discomfort).",
"   </p>",
"   <p>",
"    Although a small proportion of women find sonohysterography painful, it is less painful than office hysteroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40823/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/18/22820?source=see_link\">",
"       \"Patient information: Abnormal uterine bleeding (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saline infusion sonohysterography is a procedure in which fluid is instilled into the uterine cavity transcervically to provide enhanced endometrial visualization during transvaginal ultrasound examination. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American Institute for Ultrasound in Medicine's standard indications and contraindications to this procedure are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef73097 \" href=\"mobipreview.htm?6/51/6971\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with abnormal uterine bleeding in whom endometrial sampling is indicated, a clinician may obtain saline instillation sonohysterography prior to the sampling procedure. Blind sampling procedures are most useful if an abnormality is symmetrically 'pan uterine'. When focal lesions (eg, polyps, fibroids, some hyperplasias, some carcinomas) are detected, then directed biopsies are preferable. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Unscheduled uterine bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Saline infusion sonohysterography is useful for detecting potential anatomic causes of reduced fertility, such as submucous myomas, endometrial polyps, anomalies, and intrauterine adhesions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Infertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The examination is scheduled when the endometrium will be as thin as possible from the last day or two of staining until three to four days after the bleeding has ended. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that the balloon catheter be inserted intracervically rather than intrauterine into the uterus to minimize pain and saline volume. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of upper genital tract infection is similar to that with a traditional hysterosalpingogram. Whether cultures are obtained and prophylactic antibiotics prescribed depends upon the patient's risk factors and clinician preference. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      False positive findings have been attributed to blood clots, intrauterine debris, mucus plugs, shearing of normal endometrium, thickened endometrial folds, and misidentified endometrial fragments. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'False positive findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Procedure-related side effects and complications are mild and uncommon. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Side effects and complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/1\">",
"      Parsons AK, Lense JJ. Sonohysterography for endometrial abnormalities: preliminary results. J Clin Ultrasound 1993; 21:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/2\">",
"      Syrop CH, Sahakian V. Transvaginal sonographic detection of endometrial polyps with fluid contrast augmentation. Obstet Gynecol 1992; 79:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/3\">",
"      American College of Obstetricians and Gynecologists. ACOG Technology Assessment in Obstetrics and Gynecology No. 5: sonohysterography. Obstet Gynecol 2008; 112:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/4\">",
"      American Institute of Ultrasound in Medicine, American College of Radiology, American College of Obstetricians and Gynecologists, Society of Radiologists in Ultrasound. AIUM practice guideline for the performance of sonohysterography. J Ultrasound Med 2012; 31:165.",
"     </a>",
"    </li>",
"    <li>",
"     APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/6\">",
"      Goldstein RB, Bree RL, Benson CB, et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement. J Ultrasound Med 2001; 20:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/7\">",
"      La Sala GB, Blasi I, Gallinelli A, et al. Diagnostic accuracy of sonohysterography and transvaginal sonography as compared with hysteroscopy and endometrial biopsy: a prospective study. Minerva Ginecol 2011; 63:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/8\">",
"      Kamel HS, Darwish AM, Mohamed SA. Comparison of transvaginal ultrasonography and vaginal sonohysterography in the detection of endometrial polyps. Acta Obstet Gynecol Scand 2000; 79:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/9\">",
"      Epstein E, Ramirez A, Skoog L, Valentin L. Transvaginal sonography, saline contrast sonohysterography and hysteroscopy for the investigation of women with postmenopausal bleeding and endometrium &gt; 5 mm. Ultrasound Obstet Gynecol 2001; 18:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/10\">",
"      Schw&auml;rzler P, Concin H, B&ouml;sch H, et al. An evaluation of sonohysterography and diagnostic hysteroscopy for the assessment of intrauterine pathology. Ultrasound Obstet Gynecol 1998; 11:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/11\">",
"      Krampl E, Bourne T, Hurlen-Solbakken H, Istre O. Transvaginal ultrasonography sonohysterography and operative hysteroscopy for the evaluation of abnormal uterine bleeding. Acta Obstet Gynecol Scand 2001; 80:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/12\">",
"      Soares SR, Barbosa dos Reis MM, Camargos AF. Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases. Fertil Steril 2000; 73:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/13\">",
"      de Kroon CD, Jansen FW, Louw&eacute; LA, et al. Technology assessment of saline contrast hysterosonography. Am J Obstet Gynecol 2003; 188:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/14\">",
"      Goldstein SR, Zeltser I, Horan CK, et al. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol 1997; 177:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/15\">",
"      Salle B, Gaucherand P, de Saint Hilaire P, Rudigoz RC. Transvaginal sonohysterographic evaluation of intrauterine adhesions. J Clin Ultrasound 1999; 27:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/16\">",
"      Darwish AM, Youssef AA. Screening sonohysterography in infertility. Gynecol Obstet Invest 1999; 48:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/17\">",
"      Ludwin A, Ludwin I, Banas T, et al. Diagnostic accuracy of sonohysterography, hysterosalpingography and diagnostic hysteroscopy in diagnosis of arcuate, septate and bicornuate uterus. J Obstet Gynaecol Res 2011; 37:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/18\">",
"      Luciano DE, Exacoustos C, Johns DA, Luciano AA. Can hysterosalpingo-contrast sonography replace hysterosalpingography in confirming tubal blockage after hysteroscopic sterilization and in the evaluation of the uterus and tubes in infertile patients? Am J Obstet Gynecol 2011; 204:79.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/19\">",
"      Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/20\">",
"      Hann LE, Gretz EM, Bach AM, Francis SM. Sonohysterography for evaluation of the endometrium in women treated with tamoxifen. AJR Am J Roentgenol 2001; 177:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/21\">",
"      Elhelw B, Ghorab MN, Farrag SH. Saline sonohysterography for monitoring asymptomatic postmenopausal breast cancer patients taking tamoxifen. Int J Gynaecol Obstet 1999; 67:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/22\">",
"      Schwartz LB, Snyder J, Horan C, et al. The use of transvaginal ultrasound and saline infusion sonohysterography for the evaluation of asymptomatic postmenopausal breast cancer patients on tamoxifen. Ultrasound Obstet Gynecol 1998; 11:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/23\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol 2006; 107:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/24\">",
"      Goldstein SR. Controversy about uterine effects and safety of SERMs: the saga continues. Menopause 2002; 9:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/25\">",
"      Wolman I, Groutz A, Gordon D, et al. Timing of sonohysterography in menstruating women. Gynecol Obstet Invest 1999; 48:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/26\">",
"      Dessole S, Farina M, Capobianco G, et al. Determining the best catheter for sonohysterography. Fertil Steril 2001; 76:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/27\">",
"      Spieldoch RL, Winter TC, Schouweiler C, et al. Optimal catheter placement during sonohysterography: a randomized controlled trial comparing cervical to uterine placement. Obstet Gynecol 2008; 111:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/28\">",
"      Sylvestre C, Child TJ, Tulandi T, Tan SL. A prospective study to evaluate the efficacy of two- and three-dimensional sonohysterography in women with intrauterine lesions. Fertil Steril 2003; 79:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/29\">",
"      Exalto N, Stappers C, van Raamsdonk LA, Emanuel MH. Gel instillation sonohysterography: first experience with a new technique. Fertil Steril 2007; 87:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/30\">",
"      Davis PC, O'Neill MJ, Yoder IC, et al. Sonohysterographic findings of endometrial and subendometrial conditions. Radiographics 2002; 22:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/31\">",
"      Timmerman D, Verguts J, Konstantinovic ML, et al. The pedicle artery sign based on sonography with color Doppler imaging can replace second-stage tests in women with abnormal vaginal bleeding. Ultrasound Obstet Gynecol 2003; 22:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/32\">",
"      Becker E Jr, Lev-Toaff AS, Kaufman EP, et al. The added value of transvaginal sonohysterography over transvaginal sonography alone in women with known or suspected leiomyoma. J Ultrasound Med 2002; 21:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/33\">",
"      Reeves MF, Goldstein RB, Jones KD. Communication of adenomyosis with the endometrial cavity: visualization with saline contrast sonohysterography. Ultrasound Obstet Gynecol 2010; 36:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/34\">",
"      Tocci A, Greco E, Ubaldi FM. Adenomyosis and 'endometrial-subendometrial myometrium unit disruption disease' are two different entities. Reprod Biomed Online 2008; 17:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/35\">",
"      Ahonkallio SJ, Liakka AK, Martikainen HK, Santala MJ. Feasibility of endometrial assessment after thermal ablation. Eur J Obstet Gynecol Reprod Biol 2009; 147:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/36\">",
"      Cooper JM, Brady RM. Intraoperative and early postoperative complications of operative hysteroscopy. Obstet Gynecol Clin North Am 2000; 27:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/37\">",
"      Tuveng JM, Vold I, Jerve F, et al. Hysterosalpingography: value in estimating tubal function, and risk of infectious complications. Acta Eur Fertil 1985; 16:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/38\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 74. Antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2006; 108:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/39\">",
"      Bese T, Demirkiran F, Guralp O, et al. Transtubal transport of carcinoma cells into the peritoneal cavity after saline infusion via transcervical route in patients with endometrial carcinoma. Int J Gynecol Cancer 2009; 19:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/40\">",
"      Alc&aacute;zar JL, Errasti T, Zornoza A. Saline infusion sonohysterography in endometrial cancer: assessment of malignant cells dissemination risk. Acta Obstet Gynecol Scand 2000; 79:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/41\">",
"      Dessole S, Rubattu G, Farina M, et al. Risks and usefulness of sonohysterography in patients with endometrial carcinoma. Am J Obstet Gynecol 2006; 194:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/42\">",
"      Lindheim SR, Morales AJ. Comparison of sonohysterography and hysteroscopy: lessons learned and avoiding pitfalls. J Am Assoc Gynecol Laparosc 2002; 9:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/43\">",
"      Mihm LM, Quick VA, Brumfield JA, et al. The accuracy of endometrial biopsy and saline sonohysterography in the determination of the cause of abnormal uterine bleeding. Am J Obstet Gynecol 2002; 186:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/44\">",
"      Dessole S, Farina M, Rubattu G, et al. Side effects and complications of sonohysterosalpingography. Fertil Steril 2003; 80:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40823/abstract/45\">",
"      van Dongen H, de Kroon CD, van den Tillaart SA, et al. A randomised comparison of vaginoscopic office hysteroscopy and saline infusion sonography: a patient compliance study. BJOG 2008; 115:1232.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3252 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40823=[""].join("\n");
var outline_f39_55_40823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Unscheduled uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tamoxifen-induced changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Polyp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Leiomyoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hyperplasia and cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adhesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5523488\">",
"      Adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5523531\">",
"      Endometrial assessment after non-resectoscopicl endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TECHNICAL CONCERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Difficulty passing the catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Poor visualization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Dissemination of carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      False positive findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SIDE EFFECTS AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3252\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3252|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/1/16402\" title=\"diagnostic image 1A\">",
"      Sonogram pt on tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/58/19362\" title=\"diagnostic image 1B\">",
"      SIS tamoxifen patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/13/29906\" title=\"diagnostic image 2\">",
"      Irregular endometrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/32/40449\" title=\"diagnostic image 3\">",
"      Normal sonohysterogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/8/8320\" title=\"diagnostic image 4A\">",
"      Sonogram abn ut bleeding2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/41/33425\" title=\"diagnostic image 4B\">",
"      SIS endometrial polyp2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/37/5715\" title=\"diagnostic image 5\">",
"      Color Doppler endometrial polyp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/52/12097\" title=\"diagnostic image 6A\">",
"      Sonogram abn ut bleeding1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/53/21328\" title=\"diagnostic image 6B\">",
"      SIS submucous myoma1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/34/3619\" title=\"diagnostic image 7A\">",
"      Sonogram abn ut bleeding3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/39/30321\" title=\"diagnostic image 7B\">",
"      SIS abn ut bleeding3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3252|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/45/33503\" title=\"picture 1\">",
"      Hysteroscopy tamoxifen pt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/45/16095\" title=\"picture 2\">",
"      Hysteroscopic view3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3252|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/51/6971\" title=\"table 1\">",
"      Sonohysterography indications and contraindications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26679?source=related_link\">",
"      Evaluation of couples with recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41576?source=related_link\">",
"      Managing the side effects of tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/18/22820?source=related_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_55_40824="Personality disorders";
var content_f39_55_40824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Personality disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/55/40824/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/55/40824/contributors\">",
"     Kenneth R Silk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/55/40824/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/55/40824/contributors\">",
"     Andrew Skodol, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/55/40824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/55/40824/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/55/40824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 23, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Personality consists of enduring patterns of perceiving, relating to, and thinking about the environment and oneself that are exhibited across numerous social and personal contexts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/1\">",
"     1",
"    </a>",
"    ]. A personality disorder arises when personality traits are so inflexible and maladaptive across a wide range of situations that they cause significant distress and impairment of social, occupational, and role functioning. In addition, the thinking, displays of emotion, impulsivity, and interpersonal behavior of the individual must deviate markedly from the expectations of the individual's culture in order to qualify as a personality disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with personality disorders can significantly strain the doctor-patient relationship. Clinicians frequently lack training in how to recognize and manage personality disorders. In addition, until recently, research has generally lacked the methodologic rigor needed to validate diagnostic criteria and establish major treatment advances.",
"   </p>",
"   <p>",
"    Schizotypal and antisocial personality disorders will be reviewed here in most detail since these specific disorders have been widely studied, and there are sufficient data to allow meaningful discussion about the presentation, course, and treatment response. Borderline personality disorder and antisocial personality disorder are also discussed separately. Challenges to maintaining a therapeutic alliance in patients with personality disorders or traits are also discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/19/10553?source=see_link\">",
"     \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42009?source=see_link\">",
"     \"Borderline personality disorder: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/26/42409?source=see_link\">",
"     \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3769?source=see_link\">",
"     \"Treatment of antisocial personality disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20615?source=see_link\">",
"     \"Establishing and maintaining a therapeutic relationship in psychiatric practice\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to difficult patients in general are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23992?source=see_link\">",
"     \"The difficult patient encounter\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPACT OF DISORDER",
"    </span>",
"   </p>",
"   <p>",
"    Personality disorders are important risk factors for a variety of medical and psychiatric difficulties. Adverse outcomes for patients with personality disorders include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical injury from fights and accidents due to impulsive and reckless behavior [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Suicide attempts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Unplanned pregnancy and high risk sexual behavior [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Comorbid anxiety, mood,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      substance use disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Less favorable response to treatment for depression, anxiety disorder, or substance abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Functional impairment (eg, self-care, work, and interpersonal functioning) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to increased risk for these conditions, individuals with personality disorder often pose a challenge for clinicians, as features of their behavior may compromise care. Barriers to developing an effective doctor-patient alliance may arise related to patient distrust, irritability, poor communication skills, dependency, and excessive demands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients run the risk of alienating health care providers with late night phone calls, angry outbursts, repeated visits or admissions, signing out against medical advice, or being otherwise noncompliant with recommended treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23992?source=see_link\">",
"     \"The difficult patient encounter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients often lack insight regarding the connection between their behaviors and interpersonal difficulties. Patients commonly externalize their difficulties, seeing the problem as how people react to them rather than themselves as the problem, and argue that their behavior was appropriate given the provocation by another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"   </p>",
"   <p>",
"    The DSM-IV-TR criteria for diagnosing a personality disorder are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef78113 \" href=\"mobipreview.htm?38/41/39579\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    DSM-IV-TR divides the personality disorders into three clusters based upon descriptive similarities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cluster A characteristics: individuals may appear odd and eccentric",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Paranoid",
"     </li>",
"     <li>",
"      Schizoid",
"     </li>",
"     <li>",
"      Schizotypal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cluster B characteristics: individuals often appear dramatic, emotional, or erratic in their emotions and behavior",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Histrionic",
"     </li>",
"     <li>",
"      Narcissistic",
"     </li>",
"     <li>",
"      Borderline (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/19/10553?source=see_link\">",
"       \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42009?source=see_link\">",
"       \"Borderline personality disorder: Treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antisocial (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/26/42409?source=see_link\">",
"       \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3769?source=see_link\">",
"       \"Treatment of antisocial personality disorder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cluster C characteristics: Individuals often appear anxious or fearful",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Avoidant",
"     </li>",
"     <li>",
"      Dependent",
"     </li>",
"     <li>",
"      Obsessive-compulsive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A problem with the categorical approach, however, is that patients who have one personality disorder often also meet criteria for one or more additional personality disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristics of personality disorders are described in a table (",
"    <a class=\"graphic graphic_table graphicRef51279 \" href=\"mobipreview.htm?20/11/20668\">",
"     table 2",
"    </a>",
"    ). Specific diagnostic criteria are provided in a series of tables (",
"    <a class=\"graphic graphic_table graphicRef52389 graphicRef62678 graphicRef75507 graphicRef80887 graphicRef50890 graphicRef63552 graphicRef59866 graphicRef81110 graphicRef72308 graphicRef63127 \" href=\"mobipreview.htm?36/51/37695\">",
"     table 3A-J",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated international prevalence of personality disorders is 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/10\">",
"     10",
"    </a>",
"    ]. Personality disorders are significantly more common in males, the young, poorly educated, and unemployed. These disorders are highly comorbid with Axis I disorders.",
"   </p>",
"   <p>",
"    The National Epidemiologic Survey on Alcohol and Related Conditions found the community prevalence of personality disorders in the United States to be 14.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/18\">",
"     18",
"    </a>",
"    ]. In another study, personality disorders were diagnosed by structured interview in 45.5 percent of 859 patients presenting for psychiatric outpatient treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of subtypes of personality disorder among patients in the community were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/18,20,21\">",
"     18,20,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obsessive-compulsive personality disorder &mdash; 7.9 percent",
"     </li>",
"     <li>",
"      Paranoid personality disorder &mdash; 4.4 percent",
"     </li>",
"     <li>",
"      Antisocial personality disorder &mdash; 3.6 percent",
"     </li>",
"     <li>",
"      Schizotypal personality disorder &mdash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RECOGNIZING PERSONALITY DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician may feel angry, threatened, defensive, or incompetent, or may find it difficult to feel any emotional connection with the patient. Alternatively, the clinician may find him or herself preoccupied with the patient without any specific event or attribute that would reasonably induce such involvement. These clinician reactions may provide some evidence toward the consideration of a personality disorder, although they are certainly not pathognomonic for this diagnosis.",
"   </p>",
"   <p>",
"    The consistent presence of certain behaviors and traits, with onset in middle to late adolescence and continuing throughout adult life, are particularly suggestive of a personality disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frequent mood swings",
"     </li>",
"     <li>",
"      Angry outbursts",
"     </li>",
"     <li>",
"      Anxiety sufficient to cause difficulty making friends",
"     </li>",
"     <li>",
"      Need to be the center of attention",
"     </li>",
"     <li>",
"      Feeling of being widely cheated or taken advantage of",
"     </li>",
"     <li>",
"      Difficulty delaying gratification",
"     </li>",
"     <li>",
"      Not feeling there is anything wrong with their behavior (ego-syntonic symptoms)",
"     </li>",
"     <li>",
"      Externalizing and blaming the world for their behaviors and feelings",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GENERAL PATIENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A treatment plan should be developed, discussed and modified over time with input from the patient and others involved in their support. This treatment plan may include individual and group therapy, medication, self-education, substance abuse treatment, partial hospitalization, or brief hospitalization during times of crises.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Referral to a mental health professional",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are significantly impaired with personality disorder may benefit from early referral to a mental health professional. Such patients often require much time, and the primary care clinician may not have the expertise or available time to address their needs.",
"   </p>",
"   <p>",
"    However, it is also recognized that there may be a shortage of mental health resources in some areas, and especially a shortage of clinicians who are trained or skilled in working with this difficult group of patients. In particular, patients with co-morbid personality disorder associated with another diagnosis, such as depression, are less likely to respond to standard treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/11-13,23,24\">",
"     11-13,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mental health professionals vary in their level of comfort and experience treating patients with personality disorder. It is helpful to identify particular mental health professionals or treatment programs in a community that specialize in providing care for such patients.",
"   </p>",
"   <p>",
"    Coordination of care between medical and mental health providers is important, particularly when personality disorder occurs in conjunction with medical illness. Medications used to treat a variety of medical conditions (eg, glucocorticoids, beta-blockers, or interferon) may complicate the treatment of a coexisting psychiatric disorder. The use of potentially habit-forming drugs such as opioids, amphetamines, and benzodiazepines carries greater risks in patients with certain personality disorders, such as antisocial and borderline personality disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, psychotropic medications may complicate the treatment of medical conditions. In the absence of a coexistent psychiatric disorder, caution should be taken before prescribing psychotropic medication for personality disorder, with limited data supporting effectiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     The clinician-patient relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;For any patient, how a treatment plan is presented, including discussion of side effects and the usual time course to response, influences compliance with the plan. Additionally, guidelines about when and how to contact the treating clinician are helpful. This communication takes on even greater importance for patients with personality disorder. Compared to the general population, patients with personality disorder have greater sensitivity to side effects, tend to take more of a drug than prescribed and more alternative medications (herbals and other natural treatments), and are at increased risk for concurrent use of illicit drugs and alcohol.",
"   </p>",
"   <p>",
"    Dysfunctional behaviors related to medication issues, that typify some types of personality disorder, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discontinuing prescribed therapy in the belief that herbal therapy is more effective (dependent personality).",
"     </li>",
"     <li>",
"      Lying about compliance with treatment (avoidant personality).",
"     </li>",
"     <li>",
"      Misinterpretation of delay in the clinician returning a phone call, leading to feeling of rejection and acting out by stopping or overdosing on a medication (borderline personality).",
"     </li>",
"     <li>",
"      Worry about unusual side effects from a prescribed medication, such as blocking the body from absorbing essential nutrients or vitamins, or belief that they are being tricked by a generic substitution into taking something harmful (schizotypal personality)",
"     </li>",
"     <li>",
"      Becoming angry that they were not told of an infrequent or minor drug side effect they had looked up while researching their medications (obsessive-compulsive personality).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these problems are best managed by fostering a relationship in which the patient is comfortable talking about concerns, although direct communication often does not come easily to people with personality disorder. It is sometimes most efficient to tell a patient to call the office or the nurse if he should have a worry about taking the medication. One might say something such as \"I certainly do not want you to take a medication that is making you feel worse, but I would also hate to have you stop a medication because you thought you have a reaction. Often the body takes a few days to adjust to the medication so please let us know if you have concerns.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Fostering compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compliance with a treatment plan is frequently a challenge for patients with personality disorder. Limiting the number of medications needed, and the frequency of dosing, can be helpful. Most, though not all, psychiatric medications can be taken once a day.",
"   </p>",
"   <p>",
"    It is useful to inquire about compliance in a nonjudgmental way. Good communication can be promoted by questions and suggestions such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Let's see if we can sort out why the medication does not seem to be working. It's not unusual to forget to take a dose. It is always difficult to take a medication on schedule, especially if you need to take many doses a day. How often do you think you forget to take the medication in a typical week?\"",
"     </li>",
"     <li>",
"      \"Is there anything that makes it difficult for you to follow through with the treatment plan we discussed? Maybe we can modify it to make it easier for you.\"",
"     </li>",
"     <li>",
"      \"Does this plan address the medical problems that brought you here today? Do you have any questions about other things you might have heard about this?\"",
"     </li>",
"     <li>",
"      \"Is there someone whom you usually rely on to help in your medical care?\" (You might offer to give the patient an information pamphlet or recommend reading that the patient can share with a significant other. Ask if the patient would like to bring this person at the time of the next visit).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEDICATION MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no medications approved by the United States Food and Drug Administration for the treatment of personality disorders. However, patients who present with personality difficulties not infrequently have other psychiatric disorders (eg, depression, substance abuse) that should be addressed with appropriate pharmacologic treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reliable data from randomized controlled trials regarding the use of specific medications for personality disorder are not available and treatment guidelines note the paucity of trials to inform recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21\">",
"     21",
"    </a>",
"    ]. Studies suggest that it is more useful to target specific behavioral difficulties (eg, self-destructiveness, impulsivity, anger control) than view medication as a treatment for the personality disorder as a whole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21,26-29\">",
"     21,26-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Principles of prescribing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based largely on clinical experience, a number of suggestions on how to manage medications and the prescribing process for patients with personality disorder are worth considering.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discuss with the patient that the need for medications, and adjustment of medications over time, are integral factors to successful therapy. Communicate to the patient how the medication fits in with other aspects of the treatment plan.",
"     </li>",
"     <li>",
"      Maintain a realistic perspective regarding the time course and magnitude of response that is likely to be achieved with medication. Communicate this to the patient and to key members of the patient's support system (with the patient's permission). This is important to avoid \"augmenting\" the original medication too quickly, that may then lead to ineffective polypharmacy and the multiple problems associated with polypharmacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Identify target symptoms that will be the focus of the medication management and decide how you and the patient will assess changes in the severity of symptoms. These targets should be symptoms that are usually present, and that are not just manifest at times of full emotional upheaval. However, It is also important to address emotional instability as a target symptom.",
"     </li>",
"     <li>",
"      Avoid changing medication each time there is a crisis or change in mood. Crises and mood changes occur frequently and suddenly, and also remit suddenly. Prescribing medication at the time of a crisis will not provide a specific target symptom or endpoint upon which to judge a medication's effectiveness and is another path to polypharmacy.",
"     </li>",
"     <li>",
"      Recognize that, given the inherent symptom variability in patients with personality disorder, it may take a number of months to determine whether a particular medication is helpful.",
"     </li>",
"     <li>",
"      When it is determined that a medication is not providing benefit, after a reasonable time period for onset of effect, it is wiser to switch medications than to add a second or in some instances a third or fourth medication. There is no evidence that polypharmacy is effective in these patients, but polypharmacy does increase risk for side effects including sleep disturbance and weight gain.",
"     </li>",
"     <li>",
"      Provide specific information to the patient about the selected medication, side effects, and the criteria the patient should use for deciding to contact you if there are problems.",
"     </li>",
"     <li>",
"      Avoid medications likely to be fatal in overdose or that can be abused. These include benzodiazepines (especially if the patient may combine them with alcohol) and tricyclic antidepressants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/30\">",
"       30",
"      </a>",
"      ]. When potentially risky medications must be used, continued prescribing should be contingent on patient compliance with the full treatment plan, including psychotherapy appointments, abstinence from substances of abuse (can check with random urines), and continuing with job or school.",
"     </li>",
"     <li>",
"      Do not shy away from addressing the issue of suicidality. Be straightforward with the patient regarding lethality of the medication in excessive dosages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Choice of medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reviews focus on medication for personality disorder, and especially for BPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21,27-29\">",
"     21,27-29",
"    </a>",
"    ]. Treatment of borderline personality disorder and antisocial personality disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42009?source=see_link&amp;anchor=H16#H16\">",
"     \"Borderline personality disorder: Treatment and prognosis\", section on 'Pharmacotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3769?source=see_link\">",
"     \"Treatment of antisocial personality disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some medications may be useful in particular circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The selective serotonin reuptake inhibitors (SSRIs) are often thought of as first-line medical therapy for personality disorders, although there are little data from randomized trials to support this. Studies of the effectiveness of SSRI in treating depression symptoms in patients with personality disorder are inconsistent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21\">",
"       21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Evidence for SSRI use primarily focuses on reducing irritability and anger [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21,31-33\">",
"       21,31-33",
"      </a>",
"      ]. However, the methodology of several of these studies has been questioned because of recruitment issues. If effective, the effect may take up to ten weeks to become manifest and relatively high doses of the specific SSRI may be needed.",
"     </li>",
"     <li>",
"      Mood stabilizers such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      may help stabilize mood and reduce irritability",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aggression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21,28,29,34-37\">",
"       21,28,29,34-37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antipsychotic drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      may help reduce impulsive behavior, cognitive distortions, and issues related to mental state (dissociation, depersonalization). In addition, both typical and atypical antipsychotics may be effective in treating irritability and aggression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21,27-29,38-41\">",
"       21,27-29,38-41",
"      </a>",
"      ]. Antipsychotic medications have been shown to be effective in schizotypal personality disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21,42,43\">",
"       21,42,43",
"      </a>",
"      ]. Antipsychotics for patients with personality disorder are often helpful at lower doses than those used for psychotic patients.",
"     </li>",
"     <li>",
"      Benzodiazepines can lead to subjective improvement, but should be avoided due to their abuse potential and possible disinhibition of impulsive behavior [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/25\">",
"       25",
"      </a>",
"      ]. The use of a low-dose antipsychotic is preferable. If benzodiazepines must be used, one with a longer half-life (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      ) should be chosen, and the benzodiazepine should be prescribed only for a short period of time.",
"     </li>",
"     <li>",
"      There is some evidence that medications used to treat social phobia, such as the SSRIs, SNRIs, and MAOIs, can be effective in the treatment of avoidant personality disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21,44\">",
"       21,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SCHIZOTYPAL PERSONALITY DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of schizotypal personality disorder (STPD) developed out of the observation that a certain set of personality traits were more frequent in the first degree relatives of patients with schizophrenia. Population rates of this disorder are estimated to be about 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21,42\">",
"     21,42",
"    </a>",
"    ]. These patients are often not motivated to seek treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The familial association and similarities in several physiologic measures suggest that genetics play an important role in the etiology of STPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/45-47\">",
"     45-47",
"    </a>",
"    ], though the exact nature of the genetic overlap and the degree of overlap remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. A small percentage of these patients will go on to develop schizophrenia, although this becomes increasingly unlikely if psychosis does not develop before age 30 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with STPD are often viewed by those around them as odd or eccentric. They are apt to be loners and uncomfortable in social situations. They are often fascinated by unusual ideas but, unlike patients with delusions, they are willing to consider other explanations if facts are presented that challenge their theories.",
"   </p>",
"   <p>",
"    Clinically, patients with STPD are similar to patients with schizophrenia who meet criteria for having prodromal or residual symptoms but do not have delusions or hallucinations. There is consideration to reclassify STPD in the next DSM (DSM-V) with schizophrenia, but this remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    STPD may first be noticed by the clinician in the form of unusual ideas about the cause of physical symptoms. The patient may adopt ideas from nontraditional medicine (that are significantly at variance with ideas within that patient's culture) as a starting point and embellish them with his or her own creative thinking. It may be difficult for the patient to stay focused upon the symptoms being discussed, going off on tangents that have nothing to do with his or her medical problems. After a clinical encounter with a schizotypal patient, the term \"odd\" seems quite appropriate.",
"   </p>",
"   <p>",
"    At times these patients have paranoid ideas (but not frank delusions); this may result in deciding a particular clinician is critical and uncaring. The best fit is often a clinician who is willing to listen to the patient's ideas without discounting or devaluing them, and then explain his or her own approach to evaluation and treatment of the target symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with STPD most often present for mental health treatment at the urging of relatives. This may occur because of lack of success in achieving the level of occupational or educational functioning that would be expected based upon the individual's level of intelligence. Occasionally, symptoms of major depression or an anxiety disorder are the reason for presentation; in these cases, the types of treatment usually recommended for these comorbid disorders may be appropriate.",
"   </p>",
"   <p>",
"    Referral to psychiatry is useful since it is often difficult to sort out whether actual psychotic symptoms are present (which would lead to a diagnosis other than personality disorder) or whether comorbid conditions are evident that warrant additional treatment.",
"   </p>",
"   <p>",
"    Because of the links between STPD and schizophrenia, antipsychotic medications have been tried in patients with STPD. The number of studies are limited and the results are mixed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/52\">",
"     52",
"    </a>",
"    ]. There is evidence for some success with both typical and atypical antipsychotics, especially with cognitive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21,42,43\">",
"     21,42,43",
"    </a>",
"    ]. While the cognitive symptoms of schizophrenia are often not responsive to psychopharmacologic intervention, the use of antipsychotic medication in STPD can lead to a \"tightening\" of thinking. With such response, patients with STPD may have less social anxiety and exhibit less suspicion in interpersonal situations. With fewer cognitive distortions, patients can respond in ways more in line with societal expectations, and are better able to focus on the actual nature of an interchange. However, patients often still remain odd in appearance and affect and socially anxious, even when they do improve cognitively with medication treatment. For this reason, social skills training has also been recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ANTISOCIAL PERSONALITY DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology, clinical features, diagnosis, and treatment of patients with antisocial personality disorder are discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/26/42409?source=see_link\">",
"     \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3769?source=see_link\">",
"     \"Treatment of antisocial personality disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     BORDERLINE PERSONALITY DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology, clinical features, diagnosis, and treatment of patients with borderline personality disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/19/10553?source=see_link\">",
"     \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42009?source=see_link\">",
"     \"Borderline personality disorder: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OTHER PERSONALITY DISORDERS",
"    </span>",
"   </p>",
"   <p>",
"    There is little data that relates to other personality disorders. Histrionic and narcissistic personality disorders are most commonly managed by psychodynamic and psychoanalytic therapists and practitioners, and there is a paucity of data on these disorders. There is also scant data concerning schizoid and paranoid personality disorders, and most studies concern whether these disorders fit into the schizophrenia spectrum disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Collaborative Longitudinal Personality Disorders Study is evaluating the Cluster C personality disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/54\">",
"     54",
"    </a>",
"    ]. This study compares borderline personality disorder, STPD, avoidant (AvPD) and obsessive compulsive personality disorder (OCPD) on a number of measures, but at the moment, data primarily address the diagnostic reliability and stability of AvPD and OCPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Most of the current work on OCPD deals with trying to separate OCPD from obsessive-compulsive disorder, and the role of this personality structure in some other psychiatric disorders, especially eating disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/56\">",
"     56",
"    </a>",
"    ]. Similarly, research into AvPD attempts to explore the overlap between social phobia and AvPD and whether treatments for social phobia also apply to AvPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/10/16546?source=see_link\">",
"       \"Patient information: Borderline personality disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33249?source=see_link\">",
"       \"Patient information: Antisocial personality disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A personality disorder arises when an individual's personality traits are so inflexible and maladaptive across a wide range of situations that they cause significant impairment and distress (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients with personality disorders are at increased risk for adverse outcomes related to physical trauma, suicide, substance abuse, and concurrent psychiatric disorders. Additionally, patients often have difficulty understanding their condition and establishing rapport with their clinician (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Impact of disorder'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Personality disorders are defined by specified DSM-IV-R criteria (",
"      <a class=\"graphic graphic_table graphicRef78113 \" href=\"mobipreview.htm?38/41/39579\">",
"       table 1",
"      </a>",
"      ), and specific types of personality disorders are grouped in three clusters and defined separately (",
"      <a class=\"graphic graphic_table graphicRef51279 \" href=\"mobipreview.htm?20/11/20668\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first sign that a patient has a personality disorder is often the clinician's discomfort with the doctor-patient relationship. Behavioral patterns typical of personality disorder include frequent mood swings, difficulty making friends, feeling cheated or taken advantage of, blaming others, and difficulty with delaying gratification. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Recognizing personality disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with personality disorder may benefit from early referral to a mental health professional. Potentially habit-forming drugs, as well as drugs with a high potential for lethality in overdose, should be avoided when possible. Communication is essential between patient and clinician, and is facilitated by setting appropriate patient expectations and being non-judgmental. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'General patient approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence is limited on the effectiveness of psychotropic medication for personality disorder, in the absence of concurrent psychiatric illness (Axis I) that in itself may be responsive to medication. Care should be taken to avoid polypharmacy. Target symptoms should be identified and monitored when medication is initiated and medications should not be changed at times of crisis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Principles of prescribing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benzodiazepines should be avoided, when possible. If needed, longer acting formulations (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      ) are less likely to be abused. Selective serotonin reuptake inhibitors (SSRIs) may reduce irritability, but higher than average doses may be needed. Antipsychotic drugs may also decrease irritability and aggression, and may be helpful at doses lower than those used for patients with psychoses. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Choice of medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with schizotypal personality disorder (STPD) are often loners with unusual ideas but they are not delusional. Social skills training and antipsychotic medications may be helpful. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Schizotypal personality disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with antisocial personality disorder (ASPD) exhibit behavioral problems before age 15 and, as adults, have recurring difficulties with illegal behaviors, impulsivity, physical assault, and job retention. Effective interventions for ASPD are unknown, although comorbid psychiatric diagnoses should be appropriately treated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/26/42409?source=see_link\">",
"       \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. American Psychiatric Association, Washington, DC 2000. p.686.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/2\">",
"      Dumais A, Lesage AD, Boyer R, et al. Psychiatric risk factors for motor vehicle fatalities in young men. Can J Psychiatry 2005; 50:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/3\">",
"      Cadoret RJ, Leve LD, Devor E. Genetics of aggressive and violent behavior. Psychiatr Clin North Am 1997; 20:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/4\">",
"      Caspi A, Begg D, Dickson N, et al. Personality differences predict health-risk behaviors in young adulthood: evidence from a longitudinal study. J Pers Soc Psychol 1997; 73:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/5\">",
"      Soloff PH, Fabio A. Prospective predictors of suicide attempts in borderline personality disorder at one, two, and two-to-five year follow-up. J Pers Disord 2008; 22:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/6\">",
"      Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 1999; 56:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/7\">",
"      Zanarini MC, Parachini EA, Frankenburg FR, et al. Sexual relationship difficulties among borderline patients and axis II comparison subjects. J Nerv Ment Dis 2003; 191:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/8\">",
"      Daley SE, Burge D, Hammen C. Borderline personality disorder symptoms as predictors of 4-year romantic relationship dysfunction in young women: addressing issues of specificity. J Abnorm Psychol 2000; 109:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/9\">",
"      Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007; 64:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/10\">",
"      Huang Y, Kotov R, de Girolamo G, et al. DSM-IV personality disorders in the WHO World Mental Health Surveys. Br J Psychiatry 2009; 195:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/11\">",
"      Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry 2006; 188:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/12\">",
"      Hansen B, Vogel PA, Stiles TC, G&ouml;testam KG. Influence of co-morbid generalized anxiety disorder, panic disorder and personality disorders on the outcome of cognitive behavioural treatment of obsessive-compulsive disorder. Cogn Behav Ther 2007; 36:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/13\">",
"      Jansson I, Hesse M, Fridell M. Personality disorder features as predictors of symptoms five years post-treatment. Am J Addict 2008; 17:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/14\">",
"      King-Casas B, Sharp C, Lomax-Bream L, et al. The rupture and repair of cooperation in borderline personality disorder. Science 2008; 321:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/15\">",
"      Cox BJ, Sareen J, Enns MW, et al. The fundamental structure of axis II personality disorders assessed in the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2007; 68:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/16\">",
"      Grant BF, Stinson FS, Dawson DA, et al. Co-occurrence of DSM-IV personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Compr Psychiatry 2005; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/17\">",
"      Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis II comorbidity of borderline personality disorder. Compr Psychiatry 1998; 39:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/18\">",
"      Grant BF, Chou SP, Goldstein RB, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2008; 69:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/19\">",
"      Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry 2005; 162:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/20\">",
"      Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, and disability of personality disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2004; 65:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/21\">",
"      Herpertz SC, Zanarini M, Schulz CS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry 2007; 8:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/22\">",
"      Langbehn DR, Pfohl BM, Reynolds S, et al. The Iowa Personality Disorder Screen: development and preliminary validation of a brief screening interview. J Pers Disord 1999; 13:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/23\">",
"      Gabbard, GO, Simonsen, E. The impact of personality and personality disorders on the treatment of depression. Personal Ment Health 2007; 1:.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/24\">",
"      Bieling, PJ, Green, SM, Macqueen, G. The impact of personality disorders on treatment outcome in bipolar disorder: A review. Personal Ment Health 2007; 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/25\">",
"      Hatzitaskos P, Soldatos CR, Kokkevi A, Stefanis CN. Substance abuse patterns and their association with psychopathology and type of hostility in male patients with borderline and antisocial personality disorder. Compr Psychiatry 1999; 40:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/26\">",
"      Soloff PH. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin 1998; 62:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/27\">",
"      Binks CA, Fenton M, McCarthy L, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 2006; :CD005653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/28\">",
"      Nos&egrave; M, Cipriani A, Biancosino B, et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2006; 21:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/29\">",
"      Duggan, C, Huband, N, Smailagic, N, et al. The use of pharmacological treatments for people with personality disorder: A systematic review of randomized controlled trials. Personal Ment Health 2008; 2:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/30\">",
"      Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. Br Med J (Clin Res Ed) 1987; 295:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/31\">",
"      Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/32\">",
"      Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/33\">",
"      Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/34\">",
"      Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005; 57:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/35\">",
"      Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/36\">",
"      Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005; 162:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/37\">",
"      Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/38\">",
"      Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/39\">",
"      Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/40\">",
"      Soloff PH, George A, Nathan RS, et al. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986; 43:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/41\">",
"      Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/42\">",
"      Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003; 64:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/43\">",
"      Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986; 43:680.",
"     </a>",
"    </li>",
"    <li>",
"     Campbell-Sills, L, Stein, MB. Social phobia. In: Cambridge Textbook of Effective Treatments in Psychiatry, Tyrer, P, Silk, KR (Eds), Cambridge University Press, Cambridge 2008. p.563.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/45\">",
"      Battaglia M, Fossati A, Torgersen S, et al. A psychometric-genetic study of schizotypal disorder. Schizophr Res 1999; 37:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/46\">",
"      Keefe RS, Silverman JM, Mohs RC, et al. Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. Arch Gen Psychiatry 1997; 54:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/47\">",
"      Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry 2004; 161:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/48\">",
"      Vohs JL, Hetrick WP, Kieffaber PD, et al. Visual event-related potentials in schizotypal personality disorder and schizophrenia. J Abnorm Psychol 2008; 117:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/49\">",
"      Raine A. Schizotypal personality: neurodevelopmental and psychosocial trajectories. Annu Rev Clin Psychol 2006; 2:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/50\">",
"      Hazlett EA, Buchsbaum MS, Haznedar MM, et al. Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients. Schizophr Res 2008; 101:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/51\">",
"      Kendler KS. Diagnostic approaches to schizotypal personality disorder: a historical perspective. Schizophr Bull 1985; 11:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/52\">",
"      Coccaro EF. Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects. J Clin Psychiatry 1998; 59 Suppl 1:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/53\">",
"      Kendler KS, Czajkowski N, Tambs K, et al. Dimensional representations of DSM-IV cluster A personality disorders in a population-based sample of Norwegian twins: a multivariate study. Psychol Med 2006; 36:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/54\">",
"      Skodol AE, Gunderson JG, Shea MT, et al. The Collaborative Longitudinal Personality Disorders Study (CLPS): overview and implications. J Pers Disord 2005; 19:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/55\">",
"      McGlashan TH, Grilo CM, Sanislow CA, et al. Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders: toward a hybrid model of axis II disorders. Am J Psychiatry 2005; 162:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40824/abstract/56\">",
"      Halmi KA, Tozzi F, Thornton LM, et al. The relation among perfectionism, obsessive-compulsive personality disorder and obsessive-compulsive disorder in individuals with eating disorders. Int J Eat Disord 2005; 38:371.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6617 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-FD20FAF05D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40824=[""].join("\n");
var outline_f39_55_40824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPACT OF DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RECOGNIZING PERSONALITY DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GENERAL PATIENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Referral to a mental health professional",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      The clinician-patient relationship",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Fostering compliance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEDICATION MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Principles of prescribing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Choice of medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SCHIZOTYPAL PERSONALITY DISORDER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ANTISOCIAL PERSONALITY DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      BORDERLINE PERSONALITY DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OTHER PERSONALITY DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/6617\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/6617|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/41/39579\" title=\"table 1\">",
"      Criteria personality disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/11/20668\" title=\"table 2\">",
"      Personality disorders in DSM IV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/60/19403\" title=\"table 3A\">",
"      Criteria paranoid personality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/11/11451\" title=\"table 3B\">",
"      Criteria schizoid personality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/46/19179\" title=\"table 3C\">",
"      Criteria schizotype personality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/18/43307\" title=\"table 3D\">",
"      DSM-IV-TR dx criteria for antisocial personality disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/57/18331\" title=\"table 3E\">",
"      Criteria histrionic personality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/39/22139\" title=\"table 3F\">",
"      Criteria narcissistic personal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/55/17275\" title=\"table 3G\">",
"      Criteria avoidant personality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/12/27851\" title=\"table 3H\">",
"      Criteria dependent personality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/2/25643\" title=\"table 3I\">",
"      Criteria obsessive personality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/42/43691\" title=\"table 3J\">",
"      DSM-IV-TR BPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/26/42409?source=related_link\">",
"      Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/19/10553?source=related_link\">",
"      Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42009?source=related_link\">",
"      Borderline personality disorder: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20615?source=related_link\">",
"      Establishing and maintaining a therapeutic relationship in psychiatric practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33249?source=related_link\">",
"      Patient information: Antisocial personality disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/10/16546?source=related_link\">",
"      Patient information: Borderline personality disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23992?source=related_link\">",
"      The difficult patient encounter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3769?source=related_link\">",
"      Treatment of antisocial personality disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_55_40825="Tumor necrosis factor-alpha inhibitors: An overview of adverse effects";
var content_f39_55_40825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/55/40825/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/55/40825/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/55/40825/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/55/40825/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/55/40825/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/55/40825/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/55/40825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of tumor necrosis factor (TNF)-alpha represent important treatment advances in a number of inflammatory conditions, including rheumatoid arthritis, the seronegative spondyloarthropathies, and inflammatory bowel disease. TNF-alpha inhibitors offer a targeted strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases. However, multiple adverse effects of TNF-alpha inhibition have been identified through both clinical trials and post-marketing surveillance. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Injection site reactions",
"     </li>",
"     <li>",
"      Infusion reactions",
"     </li>",
"     <li>",
"      Neutropenia",
"     </li>",
"     <li>",
"      Infections",
"     </li>",
"     <li>",
"      Demyelinating disease",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Cutaneous reactions",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      Induction of autoimmunity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Problems associated with injection site reactions, infusion reactions, neutropenia, demyelinating disease, heart failure, and some less common adverse effects will be reviewed here. Other major complications of TNF-alpha therapy, such as tuberculosis, other infections, malignancy, and induction of autoimmunity, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects associated with TNF-alpha inhibitors are potentially serious. However, these risks must be interpreted in the context of the potential benefits and of the adverse effects associated with conventional therapies for the treatment of immune-mediated diseases (eg, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ), which are also significant and, in many cases, greater.",
"   </p>",
"   <p>",
"    Thus, the decision to use an anti-TNF-alpha agent must be an individual one, based upon the specific clinical features and unique risk profile of a given patient.",
"   </p>",
"   <p>",
"    As background to the overview of adverse events associated with TNF-alpha inhibition, we provide a brief review of TNF-alpha biology and the role of this cytokine in host defense.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     TNF-alpha biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNF-alpha is synthesized initially by activated macrophages and T cells as a transmembrane precursor protein. The cytoplasmic tail of this protein is then cleaved to release soluble TNF-alpha.",
"   </p>",
"   <p>",
"    TNF-alpha, originally known as cachexin, was described in 1975 and recognized for its ability to lyse tumors in a variety of in vitro and mouse models (hence, the name \"tumor necrosis factor\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/1\">",
"     1",
"    </a>",
"    ]. The activity of TNF-alpha against tumors in laboratory models raises the possibility that inhibition of this cytokine might potentiate the clinical risk of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The biological activity of TNF-alpha requires the aggregation of three TNF-alpha monomers to form trimeric TNF-alpha, which then acts by binding to one of two types of receptors: TNFR1 or TNFR2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. TNFR1 and TNFR2 are also known as p55 and p75, respectively. The trimeric structure of the receptors mimics that of the active cytokine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TNFR1 and TNFR2 both exert multiple effects on the immune system, including the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stimulation of the release of the inflammatory cytokines interleukin (IL)-1beta, IL-6, IL-8, and GM-CSF",
"     </li>",
"     <li>",
"      Upregulation of the expression of endothelial adhesion molecules (ICAM-1, VCAM-1, E-selectin) and chemokines (MCP-1, MIP-2, RANTES and MIP-1alpha)",
"     </li>",
"     <li>",
"      Coordination of the migration of leukocytes to targeted organs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     TNF-alpha and host defenses",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNF-alpha is important for macrophage activation, phagosome activation, differentiation of monocytes into macrophages, recruitment of neutrophils and macrophages, granuloma formation, and maintenance of granuloma integrity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/6\">",
"     6",
"    </a>",
"    ]. The effects of TNF-alpha on infection have been examined in animal experiments, including models that utilize neutralizing antibodies, disrupt transcription of the gene for TNF-alpha or one of its receptors, or lead to the overexpression of soluble TNF-alpha receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/7-12\">",
"     7-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal experiments have demonstrated the importance of TNF-alpha in protection against several pathogens including Mycobacterium tuberculosis, M. avium, M. bovis, Bacillus Calmette-Guerin (BCG), Aspergillus fumigatus, Histoplasma capsulatum, Toxoplasma gondii, Cryptococcus neoformans, and Candida albicans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/8,10,13-15\">",
"     8,10,13-15",
"    </a>",
"    ]. These organisms are not killed readily by host defense mechanisms but rather are sequestered within granulomas, which are comprised of a central core of macrophages, multinucleated giant cells, and necrotic debris surrounded by macrophages and lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/16\">",
"     16",
"    </a>",
"    ]. TNF-alpha is required for the orderly recruitment of these cells and for continued maintenance of the granuloma structure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     TNF-alpha antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five inhibitors of TNF-alpha are approved for the treatment of a variety of inflammatory illnesses (eg, rheumatoid arthritis, Crohn's disease) by the United States Food and Drug Administration (FDA). These medications are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      &mdash; A soluble p75 TNF-alpha receptor fusion protein",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      &mdash; A chimeric",
"      <span class=\"nowrap\">",
"       (mouse/human)",
"      </span>",
"      anti-TNF-alpha antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      &mdash; A fully human monoclonal anti-TNF-alpha antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"       Certolizumab pegol",
"      </a>",
"      &mdash; An antigen-binding fragment (Fab') of a humanized monoclonal antibody coupled to polyethylene glycol",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"       Golimumab",
"      </a>",
"      &mdash; A human anti-TNF-alpha monoclonal antibody",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    are monoclonal antibodies.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    is a soluble, bivalent TNF-alpha receptor.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     Certolizumab pegol",
"    </a>",
"    is the antigen-binding fragment (Fab') of a humanized monoclonal antibody coupled to polyethylene glycol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'TNF inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33829?source=see_link\">",
"     \"Certolizumab pegol for treatment of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    both bind monomeric and trimeric TNF-alpha. Infliximab is a chimeric antibody with human constant region of IgG1 coupled to the variable regions of mouse anti-TNF-alpha. In contrast, adalimumab is a human monoclonal antibody comprised of the human constant region of IgG1 attached to human variable regions. Adalimumab is, therefore, a fully human monoclonal antibody.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    is a human IgG1 kappa monoclonal antibody specific for human TNF-alpha that binds to both the soluble and transmembrane bioactive forms of human TNF-alpha.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Soluble fusion protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    is a fusion protein consisting of two TNFR2 coupled to the constant region of human IgG1. In contrast to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , etanercept binds not only to trimeric TNF-alpha but also to lymphotoxin, a cytokine once known as TNF-beta whose characteristics overlap those of TNF-alpha.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pegylated Fab' fragment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     Certolizumab pegol",
"    </a>",
"    (formerly CDP870) is a covalently bonded construct consisting of an antigen binding portion of a monoclonal antibody (Fab' fragment) covalently bonded to polyethylene glycol. The addition of polyethylene glycol may reduce the antigenicity and prolong the half-life of this anti-TNF-alpha agent. In contrast to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , certolizumab does not contain an Fc portion and, therefore, does not induce complement activation, antibody-dependent cellular cytotoxicity, or apoptosis. The full impact of this structural change on the efficacy of the agent is not clear. Certolizumab is designed to be administered on a monthly basis by subcutaneous administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26921170\">",
"    <span class=\"h3\">",
"     Therapeutic differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    both have a broader clinical spectrum of activity than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    . For example, the former medications are effective in many cases of IBD and sarcoidosis as well as RA, psoriatic arthritis, and the seronegative spondyloarthropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, etanercept does not appear to be effective in IBD or in sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     Certolizumab pegol",
"    </a>",
"    first received regulatory approval for use in Crohn's disease; whether or not it has a role in the treatment of other non-RA disorders remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Injection site reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin reactions at the site of medication injection are common but usually minor problems with subcutaneously administered agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    ). As an example, the cumulative incidence in a six-month study of etanercept was 37 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/21\">",
"     21",
"    </a>",
"    ]. Injection site reactions typically occur during the first month of treatment and last for three to five days, but they lead to discontinuation of the medication in only a small number of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion reactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    are classified as one of two types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute &mdash; Acute reactions are those that occur within 24 hours. Such reactions usually occur between 10 minutes and 4 hours after the start of the infusion.",
"     </li>",
"     <li>",
"      Delayed &mdash; Delayed reactions develop between 1 and 14 days after the start of treatment but typically occur after five to seven days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both acute and delayed infusion reactions can be characterized further as mild, moderate, or severe, depending upon the accompanying signs and symptoms. Approximately 90 percent of infusion reactions that occur with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    are acute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Acute infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute infusion reactions sometimes represent true allergies, ie, IgE-mediated type I (anaphylactic) reactions that include hypotension, bronchospasm, wheezing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urticaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    True anaphylactic reactions occur in some patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the great majority of acute infusion reactions that occur with infliximab treatment is characterized more by nonspecific symptoms and is classified more accurately as anaphylactoid (nonallergic) reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/23\">",
"     23",
"    </a>",
"    ]. These reactions are not mediated by IgE.",
"   </p>",
"   <p>",
"    The frequency and severity of acute infusion reactions were evaluated in a study of 165 consecutive patients who received a total of 479",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    infusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/22\">",
"     22",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sixteen of the patients (10 percent) experienced at least one infusion reaction.",
"     </li>",
"     <li>",
"      The percentage of infusions that were complicated by a reaction was 6.1 percent.",
"     </li>",
"     <li>",
"      Mild, moderate, or severe reactions occurred in 3.1 percent, 1.2 percent, and 1.0 percent of infusions, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nature of infusion reactions that occur in the clinic often remains poorly defined. However, two findings in the previous study suggest that the acute infusion reactions did not represent IgE-mediated anaphylactic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The reactions were generally managed successfully by reducing the rate of infusion. This approach to management would not have been effective for anaphylactic reactions.",
"     </li>",
"     <li>",
"      In a substudy of 11 patients who suffered a total of 14 acute infusion reactions, both serum tryptase and serum IgE levels were normal in all six patients in whom they were measured [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Delayed infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed infusion reactions resemble serum sickness in the timing of their onset and their association with skin rash, diffuse joint pains, myalgias, and fatigue, sometimes accompanied by fever. Delayed reactions may represent mild type III (immune complex-mediated) reactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of strategies are helpful in preventing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    infusion reactions. Through the use of such strategies, infliximab can usually be readministered even to patients who have previously experienced severe (non-anaphylactic) reactions.",
"   </p>",
"   <p>",
"    Preventive strategies include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premedication with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      (25 to 50 mg) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (650 mg) 90 minutes prior to infusion. Alternatively, patients can be given a second-generation, non-sedating antihistamine (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      10 mg daily) for five days prior to the infusion.",
"     </li>",
"     <li>",
"      Use of a test dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      . The test dose begins at a rate of 10",
"      <span class=\"nowrap\">",
"       mL/hour,",
"      </span>",
"      followed by an increase of the infusion rate as tolerated every 15 minutes until the usual rate of 125",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      is reached.",
"     </li>",
"     <li>",
"      For patients with a history of anaphylaxis after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (50 mg every eight hours) should be given over the 24 hours prior to infliximab infusion, in addition to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    appears to reduce the risk of infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/25\">",
"     25",
"    </a>",
"    ]. Strategies designed to combat the effects of antibodies that some patients develop to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the vast majority of acute infusion reactions that occur with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    are not mediated by IgE and are not anaphylactic. The approach to treatment depends upon whether the reaction is graded as mild, moderate, or severe (",
"    <a class=\"graphic graphic_table graphicRef85654 \" href=\"mobipreview.htm?4/59/5055\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef85655 \" href=\"mobipreview.htm?36/52/37696\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/26\">",
"     26",
"    </a>",
"    ]. Many reactions respond to stopping the infusion temporarily and providing hydration,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Delayed infusion reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    can usually be treated with the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (650 mg four times daily) and an antihistamine, either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg daily or twice daily) or a second-generation antihistamine (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    10 mg daily).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26921246\">",
"    <span class=\"h2\">",
"     Cytopenias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia may occur in patients on TNF-alpha inhibitors but is usually mild; other cytopenias are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/27\">",
"     27",
"    </a>",
"    ]. Pancytopenia and aplastic anemia are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26921253\">",
"    <span class=\"h3\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decrease in the number of peripheral blood neutrophils is common in patients who receive TNF-alpha inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/27\">",
"     27",
"    </a>",
"    ]. Neutropenia, defined as less than 2 X 10",
"    <sup>",
"     9",
"    </sup>",
"    <span class=\"nowrap\">",
"     cells/L,",
"    </span>",
"    occurred during treatment with these medications in 19 percent of 367 patients with inflammatory arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/27\">",
"     27",
"    </a>",
"    ]. Levels of less than 1.5 X",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    were seen in 9 percent. The mechanism by which neutropenia occurs on these medications has not been defined.",
"   </p>",
"   <p>",
"    The risk of neutropenia was significantly higher in patients with a past history of neutropenia while receiving other disease-modifying antirheumatic drugs (hazard ratio 3, 95% CI 1.7-5.3). Patients with neutropenia also had significantly lower baseline neutrophil counts compared with those who did not (4.2 X",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    , 95% CI 3.8-4.6, versus 6.2 X",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L,",
"    </span>",
"    95% CI 6.0-6.5). Similar findings were seen regardless of the clinical response to treatment and whether or not patients were also receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A decrease in neutrophils was seen in 74 percent of patients after two weeks of therapy (mean decrease in neutrophil counts of 1.1 X",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L,",
"    </span>",
"    95% CI 0.9-1.3). Other white cell subsets, including lymphocytes, monocytes, and basophils, tended to increase (0.3, 0.6, and 0.1 X",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L,",
"    </span>",
"    respectively).",
"   </p>",
"   <p>",
"    Most patients with neutropenia did not require discontinuation of therapy, but persistence or recurrence was often seen in those switched to another TNF-alpha inhibitor. Serious infections occurred in 6 percent (4 of 69) of the patients who experienced neutropenia (less than 2 X",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L).",
"    </span>",
"    Less than 1 percent (three) of all patients in the cohort developed a neutrophil count less than 0.5 X",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L.",
"    </span>",
"   </p>",
"   <p>",
"    Because of the risk of neutropenia among patients treated with TNF-alpha inhibitors, it is appropriate to check a complete blood count within one month of starting a TNF-alpha inhibitor and then to repeat this test every three to six months, assuming that the patient&rsquo;s white blood cell count is stable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNF-alpha is an important component of the immune system's response to a variety of infections, and use of TNF-alpha inhibitors has been associated with an increased risk of serious infections. These include bacterial infections (particularly pneumonia), tuberculosis, and opportunistic infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening for latent tuberculosis infection should be performed before the initiation of TNF-alpha inhibitor therapy because of the increased risk of reactivation of latent tuberculosis. Patients with evidence of latent tuberculosis should initiate treatment for latent tuberculosis before starting a TNF-alpha inhibitor. The appropriate timing for starting a TNF-alpha inhibitor in such patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link&amp;anchor=H15#H15\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\", section on 'Screening and prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link&amp;anchor=H17#H17\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\", section on 'Latent TB infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Demyelinating disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential link between TNF-alpha inhibitors and demyelinating disease has been suggested but not proven. Concern regarding demyelination or the exacerbation of intercurrent demyelinating diseases in patients treated with TNF-alpha inhibitors stems from the use of a TNF-alpha inhibitor prototype, lenercept, in multiple sclerosis (MS). Lenercept, a recombinant TNF-alpha receptor p55-immunoglobulin fusion protein (sTNFR-IgG p55), was halted in clinical testing because of concerns related to adverse effects. In a clinical trial of 168 MS patients, those treated with lenercept had more frequent and severe exacerbations of MS than did the patients taking placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With regard to TNF-alpha inhibitors approved by the FDA, a 2001 review of cases of demyelinating disease in the FDA database revealed 19 associated with the use of these agents, 17 with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and 2 with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/30\">",
"     30",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    had not been approved for clinical use at that time.",
"   </p>",
"   <p>",
"    The following findings were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of demyelination included confusion, ataxia, dysesthesia, and paresthesia.",
"     </li>",
"     <li>",
"      Neurologic findings included facial nerve palsy, optic neuritis, hemiparesis, transverse myelitis, and ascending motor neuropathy consistent with the Guillain-Barr&eacute; syndrome.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging findings suggestive of demyelination were present in the brain or spinal cord in most patients.",
"     </li>",
"     <li>",
"      All neurologic events had a temporal relationship to anti-TNF-alpha therapy, and all improved partially or completely upon discontinuation of such therapy. One patient who had anti-TNF-alpha therapy reintroduced experienced a recurrence of symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the time that the 17 cases of demyelinating disease associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    use were reported, 77,152 patients received etanercept therapy, representing a total of 55,313 patient-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/30\">",
"     30",
"    </a>",
"    ]. The incidence of demyelinating disease in patients receiving etanercept was 31 per 100,000 patient-years of exposure, compared with 4 to 6 per 100,000 per year for the general population.",
"   </p>",
"   <p>",
"    In addition to the postmarketing reports of demyelinating disease filed with the FDA, optic neuritis has been reported in association with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/31\">",
"     31",
"    </a>",
"    ]. Demyelinating peripheral nervous system disease has also been reported with these drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data do not conclusively establish a causal relationship between TNF-alpha inhibitors and demyelinating disease. Nevertheless, it seems reasonable to avoid the use of anti-TNF-alpha agents in patients with established diseases that are associated with demyelination, such as MS. In addition, anti-TNF-alpha therapy should be discontinued immediately in any patient with suspected demyelination. Some RA experts are also cautious about using TNF-alpha inhibitors in patients with family histories of MS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link\">",
"     \"Diagnosis of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Targeted TNF-alpha inhibitor use may be associated with heart failure (HF). Concern about this possible adverse effect stems from randomized clinical trials of TNF-alpha inhibitors as a potential therapy for HF and from postmarketing surveillance data gathered by the FDA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Clinical trials in HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    were performed with the hypothesis that TNF-alpha inhibition would improve cardiac function in patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two major randomized, placebo-controlled trials evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    as a possible therapy HF: the RENAISSANCE trial and the RECOVER trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Patients with New York Heart Association class II to IV chronic heart failure (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) and a left ventricular ejection fraction less than 31 percent were enrolled. The two trials differed in the dose of etanercept used. The primary end point in both trials was clinical status at 24 weeks. In addition, analysis of the effect of the two higher doses of etanercept on the combined outcome of death or hospitalization due to chronic HF from the two studies was also planned. That study was termed RENEWAL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the RENAISSANCE trial (925 patients), the three treatment groups were placebo,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    25 mg twice weekly, and etanercept 25 mg three times a week. The key finding was a trend towards higher mortality in etanercept-treated subjects, with an apparent dose&ndash;response relationship. The mortality rates were 14.2 percent, 17.9 percent, and 19.8 percent, in the three groups, respectively.",
"   </p>",
"   <p>",
"    In the RECOVER trial (1123 patients), the three treatment groups were placebo,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    25 mg once weekly, and etanercept 25 mg twice weekly. The mortality rates for the placebo, etanercept once a week, and etanercept twice a week groups were 8.8 percent, 5.9 percent, and 7.2 percent, respectively.",
"   </p>",
"   <p>",
"    In the combined analysis of these two trials (ie, RENEWAL),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    was found to have no effect on the death or chronic HF hospitalization end point. The relative risk for etanercept-treated patients was 1.1 (95% CI 0.9-1.3). On the basis of prespecified stopping rules, both trials were terminated prematurely because of futility. In addition to excluding any clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic HF, RENEWAL also raised concerns about the possible exacerbation of HF in some patients treated with TNF-alpha inhibitors.",
"   </p>",
"   <p>",
"    These concerns were confirmed in a trial involving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    as a therapy for HF, known as the ATTACH trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/36\">",
"     36",
"    </a>",
"    ]. In this trial, the major inclusion criteria were New York Heart Association class III or IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) and a left ventricular ejection fraction less than 35 percent. One hundred and fifty patients were divided into three treatment groups: placebo, infliximab 5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and infliximab 10",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Infliximab was administered by intravenous infusion at weeks zero, two, and six. No infliximab was given after week six, and patients were followed for one year.",
"   </p>",
"   <p>",
"    An analysis of all-cause mortality at one year showed that deaths were highest in the high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    arm. There were eight deaths (16 percent) in the infliximab 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    group, compared with four (8 percent) in both the infliximab 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and placebo groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     FDA reports of HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA published a summary of 47 cases of HF associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    reported to the Adverse Events Response System (AERS) through January, 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/37\">",
"     37",
"    </a>",
"    ]. Thirty-eight of these patients developed new-onset HF, and nine experienced an HF exacerbation.",
"   </p>",
"   <p>",
"    Among the 38 patients with new-onset HF, 19 had no identifiable risk factors such as coronary artery disease, hypertension, history of myocardial infarction, or diabetes, and 10 were under the age of 50 years. After TNF-alpha inhibition was discontinued and therapy for HF began, 3 of these 10 patients had complete resolution of HF, six improved, and one died.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Adalimumab and HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the adverse experiences reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    with regard to HF, no treatment trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    in HF have ever been attempted.",
"   </p>",
"   <p>",
"    With regard to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    and HF, a review of the safety of adalimumab in global clinical trials was released by Abbott Pharmaceuticals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/38\">",
"     38",
"    </a>",
"    ]. Among 10,050 patients with RA of at least three years' duration who had a total of 12,066 patient-years of exposure to adalimumab, the event rate of HF was 0.26 per 100 patient-years. The HF event rate in 542 patients with less than three years of RA and 917 patient-years of exposure was 0.11 per 100 patient-years. A lower HF event rate (0.05 per 100 patient-years) was noted in an analysis of United States postmarketing safety of adalimumab with 55,384 patient-years of exposure from 2002 to 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Registry data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a registry of patients with rheumatic disease suggested that RA is associated with an increased risk of HF, but that this risk might be attenuated by TNF inhibition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/40\">",
"     40",
"    </a>",
"    ]. A two-year study of nearly 16,000 patients with either RA or osteoarthritis reported that HF was more common among patients with RA than those with osteoarthritis (3.9 versus 2.3 percent), even after adjustment for differences in baseline demographic characteristics. However, HF was less common among RA patients treated with TNF inhibitors (3.1 versus 3.8 percent), even after adjustments for baseline HF risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the risk of HF with the use of TNF-alpha inhibitors at the FDA-approved doses are inconclusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/41\">",
"     41",
"    </a>",
"    ]. However, the labels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    contain the following disease-related concern: \"Use with caution in patients with HF or decreased left ventricular function; worsening and new-onset HF has been reported.\" In addition, infliximab is contraindicated at doses higher than 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in patients with moderate or severe HF (NYHA class",
"    <span class=\"nowrap\">",
"     III/IV)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ). The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    labels include similar wording.",
"   </p>",
"   <p>",
"    Given the evidence to date, in patients with symptomatic HF, we suggest that treatment strategies other than TNF-alpha inhibitors should be employed. In a patient who develops HF while on a TNF-alpha inhibitor, a drug-induced cause should be suspected, and use of the medication should be suspended.",
"   </p>",
"   <p>",
"    For patients with RA and mild (NYHA functional class I or II) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) HF whose arthritis is refractory to other DMARDs or biologic agents, targeted TNF-alpha inhibition might be considered. If the use of anti-TNF-alpha treatment is entertained, we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiology consultation",
"     </li>",
"     <li>",
"      Baseline echocardiography",
"     </li>",
"     <li>",
"      Close follow-up",
"     </li>",
"     <li>",
"      Avoidance of high TNF-alpha inhibitor doses (eg, more than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      3",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      40 mg every two weeks, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      50",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"     </li>",
"     <li>",
"      Prompt discontinuation of anti-TNF-alpha therapy if HF worsens",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNF inhibitors have been used for the treatment of various lung diseases and for systemic inflammatory rheumatic disorders with or without pulmonary manifestations. Adverse effects on the lung have included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Granulomatous disease &mdash; There are a number of case reports of sarcoid-like disease; discontinuation of the TNF inhibitor with or without a course of glucocorticoids generally led to resolution of symptoms.",
"     </li>",
"     <li>",
"      Pulmonary",
"      <span class=\"nowrap\">",
"       fibrosis/interstitial",
"      </span>",
"      lung disease (ILD) &mdash; Most of these patients had rheumatoid arthritis, many had a background of pulmonary disease (especially ILD), and MTX use was common in this group (and can also be associated with hypersensitivity pneumonitis). Interstitial lung disease appears to have a poorer prognosis than granulomatous disease; some patients die of pulmonary fibrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of several pulmonary diseases, including asthma, sarcoidosis, and pulmonary fibrosis, has resulted at best in inconsistent benefit, usually described in case reports or small studies, but not replicated in larger trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/42\">",
"     42",
"    </a>",
"    ]. Benefit has not been observed in chronic obstructive pulmonary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of hepatotoxicity associated with TNF-alpha inhibitors appears to be small. As of January, 2004, at least 35 postmarketing reports of severe hepatic reactions had been received by the FDA, leading to a warning to healthcare professionals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/43\">",
"     43",
"    </a>",
"    ]. Various types of hepatic involvement have been noted, including acute liver failure, hepatitis, and cholestasis. Fatal liver disease and cases requiring liver transplantation have been reported.",
"   </p>",
"   <p>",
"    The majority of these reports pertain to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . The drug label for infliximab carries a warning about the possibility of severe hepatic reactions, with jaundice or marked increase in serum alanine or aminotransferases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Use in hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data exist related to the use of TNF-alpha inhibitors in patients infected with hepatitis C virus (HCV). In one study, nine non-RA patients with rheumatic manifestations of hepatitis C were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    25 mg twice weekly for three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/44\">",
"     44",
"    </a>",
"    ]. The five patients with detectable HCV RNA had no significant increases in their viral loads, and the four with undetectable HCV RNA at baseline had no reactivation. Small studies of other anti-TNF-alpha therapies in HCV-infected patients with RA have shown similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cutaneous reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of dermatologic conditions have been reported in association with TNF-alpha inhibitors. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psoriasis and psoriatic-like skin changes (see below)",
"     </li>",
"     <li>",
"      Eczematous dermatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cutaneous manifestations of systemic lupus erythematosus",
"     </li>",
"     <li>",
"      Leukocytoclastic vasculitis",
"     </li>",
"     <li>",
"      Lichen planus and lichen planus-like eruptions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cutaneous viral, bacterial, and fungal infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=see_link&amp;anchor=H13#H13\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\", section on 'Systemic lupus erythematosus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=see_link&amp;anchor=H12#H12\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\", section on 'Vasculitis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Psoriatic skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriatic skin lesions may be induced by anti-TNF-alpha therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2008 review identified 104 cases in which psoriatic skin lesions developed in patients treated with a variety of anti-TNF-alpha agents for one of several indications, including rheumatoid arthritis, spondyloarthritis, inflammatory bowel disease, and psoriatic arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/50\">",
"       50",
"      </a>",
"      ]. Partial or complete resolution occurred in many patients (77 percent), in some cases despite continued treatment with an anti-TNF-alpha agent. The incidence may be higher with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The United States Food and Drug Administration (FDA) reviewed 69 cases of new onset psoriasis, including pustular and palmoplantar disease, in patients using TNF inhibitors for autoimmune and rheumatic diseases other than psoriasis and psoriatic arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/52,54\">",
"       52,54",
"      </a>",
"      ]. Drug discontinuation resulted in improvement in the majority of patients. The FDA alert can be found at the following web address [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/55/40825/abstract/52\">",
"       52",
"      </a>",
"      ]:",
"      <br/>",
"      <br/>",
"      <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm\">",
"       www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm",
"      </a>",
"      (accessed September 30, 2010)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of malignancy associated with the use of TNF-alpha inhibitors is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Autoimmunity and autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of autoimmunity associated with the use of TNF-alpha inhibitors is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Pregnancy and breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNF-alpha inhibitors are all considered category B drugs for pregnancy. The implications of pregnancy for the use of specific TNF-alpha inhibitors are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H10#H10\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'TNF inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The TNF-alpha inhibitors have multiple potential adverse events, which include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Injection site reactions",
"     </li>",
"     <li>",
"      Infusion reactions",
"     </li>",
"     <li>",
"      Neutropenia",
"     </li>",
"     <li>",
"      Infections",
"     </li>",
"     <li>",
"      Demyelinating disease",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Cutaneous reactions, including psoriasis",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      Induction of autoimmunity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infusion reactions with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      are classified as one of two types:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute &mdash; Acute reactions are those that occur within 24 hours. Such reactions usually occur between 10 minutes and four hours after the start of the infusion. Management of acute infusion reactions depends upon the severity. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute infusion reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delayed &mdash; Delayed reactions develop between 1 and 14 days after the start of treatment, but typically occur after five to seven days. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Delayed infusion reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TNF-alpha inhibitors have been associated with the development or exacerbation of neurologic disorders associated with demyelination, such as multiple sclerosis. However, the true nature of this association (real or spurious) has not been established. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Demyelinating disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anti-TNF-alpha therapy should be discontinued immediately in any patient with suspected demyelination. Reported neurologic findings include confusion, ataxia, dysesthesia, paresthesia, facial nerve palsy, optic neuritis, hemiparesis, transverse myelitis, and ascending motor neuropathy.",
"     </li>",
"     <li>",
"      Targeted TNF-alpha inhibitor use may be associated with the development or exacerbation of heart failure (HF). Concern about this possible adverse effect stems from randomized clinical trials of TNF-alpha inhibitors as a potential therapy for HF and from postmarketing surveillance data gathered by the FDA. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the evidence to date, patients with symptomatic HF should be treated with strategies other than TNF-alpha inhibitors. In a patient who develops HF while on a TNF-alpha inhibitor, a drug-induced cause should be suspected, and use of the medication should be suspended.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/1\">",
"      Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72:3666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/2\">",
"      Beutler B, Cerami A. The biology of cachectin/TNF--a primary mediator of the host response. Annu Rev Immunol 1989; 7:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/3\">",
"      Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/4\">",
"      Zhang G. Tumor necrosis factor family ligand-receptor binding. Curr Opin Struct Biol 2004; 14:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/5\">",
"      Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168:4620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/6\">",
"      Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am 2010; 24:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/7\">",
"      Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/8\">",
"      Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 1998; 160:6072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/9\">",
"      Garcia I, Miyazaki Y, Marchal G, et al. High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas. Eur J Immunol 1997; 27:3182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/10\">",
"      Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/11\">",
"      Benini J, Ehlers EM, Ehlers S. Different types of pulmonary granuloma necrosis in immunocompetent vs. TNFRp55-gene-deficient mice aerogenically infected with highly virulent Mycobacterium avium. J Pathol 1999; 189:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/12\">",
"      Bopst M, Garcia I, Guler R, et al. Differential effects of TNF and LTalpha in the host defense against M. bovis BCG. Eur J Immunol 2001; 31:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/13\">",
"      Huffnagle GB, Toews GB, Burdick MD, et al. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 1996; 157:4529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/14\">",
"      Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A 1997; 94:8093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/15\">",
"      Mehrad B, Strieter RM, Standiford TJ. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999; 162:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/16\">",
"      Randhawa PS. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 1990; 22:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/17\">",
"      Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/18\">",
"      Serio RN. Infliximab treatment of sarcoidosis. Ann Pharmacother 2003; 37:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/19\">",
"      Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/20\">",
"      Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/21\">",
"      Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/22\">",
"      Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/23\">",
"      Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005; 72:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/24\">",
"      Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/25\">",
"      Kapetanovic MC, Larsson L, Truedsson L, et al. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 2006; 8:R131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/26\">",
"      Puig Sanz L, S&aacute;ez E, Lozano MJ, et al. [Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Espa&ntilde;ol de Psoriasis de la Academia Espa&ntilde;ola de Dermatolog&iacute;a y Venereolog&iacute;a ]. Actas Dermosifiliogr 2009; 100:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/27\">",
"      Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2010; 62:764.",
"     </a>",
"    </li>",
"    <li>",
"     Prescribing information, Etanercept (Enbrel&reg;) Immunex Corporation, 10/10/2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/29\">",
"      van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/30\">",
"      Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44:2862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/31\">",
"      Simsek I, Erdem H, Pay S, et al. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2007; 66:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/32\">",
"      Shin IS, Baer AN, Kwon HJ, et al. Guillain-Barr&eacute; and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006; 54:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/33\">",
"      Eguren C, D&iacute;az Ley B, Daud&eacute;n E, et al. Peripheral neuropathy in two patients with psoriasis in treatment with infliximab. Muscle Nerve 2009; 40:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/34\">",
"      Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/35\">",
"      Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/36\">",
"      Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/37\">",
"      Kwon HJ, Cot&eacute; TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138:807.",
"     </a>",
"    </li>",
"    <li>",
"     Schiff MH, Burmester GR, Pangan AL et al. Safety of adalimumab (Humira) in global clinical trials of patients with early vs. longstanding rheumatoid arthritis (RA) (abstract SAT0044). Presented at the Annual European Congress of Rheumatology (EULAR), Vienna, Austria, 2005.",
"    </li>",
"    <li>",
"     Kent JD, Pangan AL, Fitzpatrick SB. Analysis of the US postmarketing safety of adalimumab (HUMIRA) in patients with rheumatoid arthritis during the first 2 years after approval (abstract). Presented at American College of Rheumatology Annual Meeting, San Diego, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/40\">",
"      Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/41\">",
"      Gabriel SE. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis? Arthritis Rheum 2008; 58:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/42\">",
"      Khasnis AA, Calabrese LH. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum 2010; 40:147.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration. 2004 Safety alerts for drugs, biologics, medical devices, and dietary supplements. www.fda.gov/medwatch/SAFETY/2004/safety04.htm#Remicade2 (Accessed on January 04, 2004).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/44\">",
"      Marotte H, Fontanges E, Bailly F, et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 2007; 46:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/45\">",
"      Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006; 45:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/46\">",
"      Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/47\">",
"      Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/48\">",
"      Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/49\">",
"      Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/50\">",
"      Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/51\">",
"      Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68:209.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm (Accessed on January 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/55/40825/abstract/53\">",
"      de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143:223.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174449.htm (Accessed on January 04, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7970 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-197.136.42.3-858ECED34C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40825=[""].join("\n");
var outline_f39_55_40825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TNF-alpha biology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TNF-alpha and host defenses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TNF-alpha antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Soluble fusion protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pegylated Fab' fragment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26921170\">",
"      - Therapeutic differences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Injection site reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Acute infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Delayed infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26921246\">",
"      Cytopenias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26921253\">",
"      - Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Demyelinating disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Clinical trials in HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - FDA reports of HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Adalimumab and HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Registry data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Use in hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cutaneous reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Psoriatic skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Autoimmunity and autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Pregnancy and breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7970\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7970|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?36/52/37696\" title=\"algorithm 1\">",
"      Mgmt acute infusion rxns - II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7970|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/59/5055\" title=\"table 1\">",
"      Mgmt acute infusion rxns - I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33829?source=related_link\">",
"      Certolizumab pegol for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_55_40826="Small plaque parapsoriasis";
var content_f39_55_40826=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87291%7EDERM%2F87292%7EDERM%2F87290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87291%7EDERM%2F87292%7EDERM%2F87290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Small plaque parapsoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small erythematous patches with fine scaling are characteristic of small plaque parapsoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Small plaque parapsoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small, slightly erythematous or brown/yellowish patches and thin plaques with little scaling in a patient with small plaque parapsoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digitate dermatosis (small plaque parapsoriasis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Characteristic finger-shaped, erythematous patches with an atrophic, cigarette-paper surface are present on the flanks of this patient with digitate dermatosis, a variant of small plaque parapsoriasis. Note the distribution of the lesions along the skin cleavage lines.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40826=[""].join("\n");
var outline_f39_55_40826=null;
var title_f39_55_40827="Leukocyte adhesion defects I";
var content_f39_55_40827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F53344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F53344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for leukocyte adhesion defect type I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Definitive diagnosis*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       A male or female patient with decreased intensity of expression of CD18 on neutrophils (less than 5 percent of normal) and at least one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. Mutation in the &beta;2 integrin gene.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. Absence of &beta;2 integrin mRNA in leukocytes.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Probable diagnosis*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       A male or female patient with defective expression of CD18 on leukocytes (less than 5 percent of normal) and all of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. Recurrent or persistent bacterial or fungal infections.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. Leukocytosis (WBC greater than 25,000/mm3).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3. Delayed separation of the umbilical cord and/or defective wound healing.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Possible diagnosis*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Infant with marked leukocytosis (WBC greater than 25,000/mm3) and one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. Recurrent bacterial infections.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. Severe deep-seated infection.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3. Absence of pus at sites of infection.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85 percent probability, respectively, that in 20 years they will still have the same diagnosis. Patients with a possible diagnosis are those that have some but not all of the characteristic clinical or laboratory findings of a particular disorder.",
"    </div>",
"    <div class=\"reference\">",
"     From Conley, ME, Notarangelo, LD, Etzioni, A. Clin Immunol 1999; 93:190.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40827=[""].join("\n");
var outline_f39_55_40827=null;
var title_f39_55_40828="Imaging studies shoulder";
var content_f39_55_40828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Imaging studies for the evaluation of shoulder pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Imaging modality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Limitations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plain film radiography",
"       </td>",
"       <td>",
"        First imaging modality for all shoulder pathology",
"        <br/>",
"        <br/>",
"        Often the only imaging modality needed for:",
"        <br/>",
"        Trauma",
"        <br/>",
"        Calcific tendonitis",
"        <br/>",
"        Arthritis",
"       </td>",
"       <td>",
"        Detection of:",
"        <br/>",
"        Bone bruise",
"        <br/>",
"        Subtle fractures",
"        <br/>",
"        Soft tissue pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT",
"       </td>",
"       <td>",
"        Preoperative evaluation of intra-articular fractures",
"        <br/>",
"        Post arthroplasty evaluation",
"       </td>",
"       <td>",
"        Limited soft tissue evaluation",
"        <br/>",
"        Detection of bone marrow edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRI",
"       </td>",
"       <td>",
"        Best initial modality for evaluation of soft tissue of the shoulder (rotator cuff, biceps, tendons, bursa, labrum)",
"        <br/>",
"        Evaluation of bone marrow",
"       </td>",
"       <td>",
"        Lower sensitivity for evaluation of shoulder instability/labral tear compared to MRA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone scan",
"       </td>",
"       <td>",
"        Infection after arthroplasty",
"        <br/>",
"        Suspected metastases",
"       </td>",
"       <td>",
"        Lack of anatomic localization and detail",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">",
"        Arthrography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Conventional",
"       </td>",
"       <td class=\"sublist_other\">",
"        Diagnosis and treatment of frozen shoulder (adhesive capsulitis)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Invasive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        MR arthrography",
"       </td>",
"       <td class=\"sublist_other\">",
"        Procedure of choice for evaluating shoulder instability/labral tear",
"        <br/>",
"        High suspicion of rotator cuff tear with normal MRI",
"       </td>",
"       <td class=\"sublist_other\">",
"        Invasive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        CT arthrography",
"       </td>",
"       <td class=\"sublist_other\">",
"        Rotator cuff tear, when MRI is not available or is contraindicated",
"        <br/>",
"        Shoulder instability/labral tear when MR arthrography is not available or is contraindicated",
"       </td>",
"       <td class=\"sublist_other\">",
"        Invasive",
"        <br/>",
"        Lower sensitivity for evaluation of shoulder instability/labral tear compared to MR arthrography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultrasonography",
"       </td>",
"       <td>",
"        Evaluation of:",
"        <br/>",
"        Rotator cuff tendons",
"        <br/>",
"        Biceps tendon",
"        <br/>",
"        Calcific tendonitis",
"        <br/>",
"        Subacromial space",
"        <br/>",
"        Muscle",
"        <br/>",
"        <br/>",
"        Interventional therapeutic procedures",
"       </td>",
"       <td>",
"        Not widely used or readily available in the United States",
"        <br/>",
"        Highly operator dependent",
"        <br/>",
"        Limited evaluation of very small or very large (&gt;3 cm ) tears and for partial thickness tears",
"        <br/>",
"        Limited evaluation of the labrum and bony structures",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; MRI: magnetic resonance imaging; MR arthrography: magnetic resonance arthrography; CT arthrography: computed tomography arthrography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40828=[""].join("\n");
var outline_f39_55_40828=null;
var title_f39_55_40829="Ischemic MR survival";
var content_f39_55_40829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Survival in ischemic mitral regurgitation is related to the degree of mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 228px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 303 patients with ischemic mitral regurgitation after a myocardial infarction, survival was related to the degree of mitral regurgitation graded by regurgitant volume (RVol) on Doppler echocardiography. In a multivariate analysis, an RVol &ge;30 mL/beat was a significant independent predictor of total and cardiac mortality at five years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Grigioni F, Enriquez-Sorano M, Zehr KJ, et al. Circulation 2001; 103:1759.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40829=[""].join("\n");
var outline_f39_55_40829=null;
var title_f39_55_40830="Return to play guidelines A";
var content_f39_55_40830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65756%7EPEDS%2F77229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65756%7EPEDS%2F77229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for participation in contact sports in certain cervical spine conditions, part A",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Contraindication to play",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Absolute",
"       </td>",
"       <td class=\"subtitle2\">",
"        Relative*",
"       </td>",
"       <td class=\"subtitle2\">",
"        None*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Congenital anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Odontoid agenesis, hypoplasia or os odontoidium",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type 1 Klippel-Feil&bull; mass fusion",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type 2 Klippel-Feil&Delta; congenital one-level fusion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atlanto-occipital fusion",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spina bifida occulta",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Atlantoaxial conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atlantoaxial instability",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atlantoaxial rotary fixation",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Stenosis of the spinal canal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spear tackler's spine",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Developmental stenosis of the spinal canal (canal/vertebral body ratio &lt;0.8)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\" rowspan=\"1\">",
"        Developmental stenosis of the spinal canal with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ligamentous instability",
"       </td>",
"       <td class=\"sublist_other\">",
"        X",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cervical cord neurapraxia with signs or symptoms lasting more than 36 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        X",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Multiple episodes of cervical cord neurapraxia",
"       </td>",
"       <td class=\"sublist_other\">",
"        X",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\" rowspan=\"1\">",
"        Developmental stenosis of the spinal canal with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Episode of cervical cord neurapraxia",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        X",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Intervertebral disk disease",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        X",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        MRI evidence of cord compression",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        X",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Burners",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent acute and chronic burners",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Resolved burner",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Provided individual is asymptomatic and neurologically normal and has full range of pain-free cervical motion.",
"     <br>",
"      &bull; Type 1 Klippel-Feil anomaly: a mass fusion of the cervical and upper thoracic vertebrae.",
"      <br>",
"       &Delta; Type 2 Klippel-Feil anomaly: one- or two-level cervical fusion with full range of cervical motion, with no evidence of spinal instability or the presence of cervical disk disease or other degenerative changes.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Torg, JS, Ramsey-Emrhein, JA. Cervical spine and brachial plexus injuries: Return-to-play recommendations. Phys Sportsmed 1997; 25.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for participation in contact sports in certain cervical spine conditions, part B",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Contraindication to play",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Absolute",
"       </td>",
"       <td class=\"subtitle2\">",
"        Relative*",
"       </td>",
"       <td class=\"subtitle2\">",
"        None*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Ligamentous injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mild ligamentous sprain with no laxity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ligamentous sprain with mild laxity (&lt;3.5 mm anteroposterior displacement and 11 degrees rotation)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ligamentous laxity (&gt;3.5 mm anteroposterior displacement or 11 degrees rotation)",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute cervical fracture",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vertebral body fracture with a sagittal component",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vertebral body fracture with associated posterior arch fractures and/or ligamentous laxity",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vertebral body fracture with displacement into the spinal canal",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healed fractures with associated neurologic findings or symptoms, pain, or limitation of cervical range of motion",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healed, stable, mildly displaced vertebral body fracture without a sagittal component or neural ring involvement",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healed, stable, end-plate fracture",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healed stable compression fracture of vertebral body",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healed \"clay-shoveler's\" fracture",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healed, nondisplaced Jefferson fracture",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healed, stable neural ring fractures",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Spinal fusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stable, one-level anterior or posterior surgical fusion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stable, two-level anterior or posterior surgical fusion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anterior or posterior fusion of three or more levels",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Cervical disk conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healed intervertebral disk bulge",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healed intervertebral disk herniation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intervertebral disk herniation with neurologic signs or symptoms, pain, or limitation of cervical range of motion",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Provided individual is asymptomatic and neurologically normal and has full range of pain-free cervical motion.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Torg, JS, Ramsey-Emrhein, JA. Cervical spine and brachial plexus injuries: Return-to-play recommendations. Phys Sportsmed 1997;25.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40830=[""].join("\n");
var outline_f39_55_40830=null;
var title_f39_55_40831="Plaque type psoriasis";
var content_f39_55_40831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plaque type psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 262px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plaque type psoriasis is characterized by erythematous plaques with sharply defined margins that are raised above the surrounding normal skin. A thick silvery scale is usually present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_55_40831=[""].join("\n");
var outline_f39_55_40831=null;
